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Abbreviations 
 
Ang1/2 Angiopoietin-1/2 
AGEs Advanced glycation end products 
AQP Aquaporin 
AR Aldose reductase 
ASCs Adipose-derived stem cells 
Arg1 Arginase 1 
FGF2 Basic fibroblast growth factor 
Bax Bcl-2-associated X protein 
BDNF Brain-derived neurotrophic factor 
BMSCs Bone marrow-derived stem cells 
BRB Blood-retina barrier 
CNTF Ciliary neurotrophic factor 
C3 Complement component 3 
Cfb Complement factor b 
Cx43 Connexin 43 
DAPI 4, 6-diamidino-2-phenylindole 
DME Diabetic macular edema 
ddH2O Double distilled water 
DR Diabetic retinopathy 
EGF Epidermal growth factor 
ERG Electroretinography 
FACs Fluorescence-activated cell sorter 
FCS Fetal calf serum 
FGF2 Basic fibroblast growth factor 
FITC Fluorescein isothiocyanate 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GCL Ganglion cell layer 
GDNF Glial cell-derived neurotrophic factor 
GDP Guanosine diphosphate 
GFAP Glial fibrillary acid protein 
GS Glutamine synthetase 
GTP Guanosine triphosphate 
HG High glucose 
HSCs Hematopoietic stem cells 
HSPs Heat shock proteins 
HUVECs Human umbilical cord endothelial cells 
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ICAM-1 Intercellular adhesion molecule 1 
ILM Inner limiting membrane 
INL Inner nuclear layer 
IL Interleukin 
Iba1 Ionized calcium-binding adaptor molecule 1 
MCP Monocyte chemoattractant protein 
MSCs Mesenchymal stem cells 
MMP Matrix metallopeptidase 
NADPH Nicotinamide adenine dinucleotide phosphate 
NDPKs Nucleoside-diphosphate kinases 
NG Normal glucose 
NG2 Neural/glial antigen 2 
NGF Nerve growth factor 
ONL Outer nuclear layer 
PAS Periodic acid Schiff 
PBS Phosphate-buffered saline 
PDGFR Platelet-derived growth factor receptor 
PDR Proliferative diabetic retinopathy 
PKD Polycystic kidney disease 
QPCR Quantitative polymerase chain reaction 
RD Retinal degeneration 
RFPECs Rat fat pad endothelial cells 
RNV Retinal neurovascular unit 
ROS Reactive oxygen species 
RPE Retinal pigment epithelium 
SDS Sodium dodecyl sulfate 
SD Sprague Dawley 
SMA Smooth muscle actin 
TBS Tris-buffered saline 
TBST Tris-buffered saline with Tween 20 
TGF Transforming growth factor 
TNF Tumor necrosis factor 
VEC VE-cadherin 
VEGF Vascular endothelial growth factor 
VEGFR2 Vascular endothelial growth factor receptor 2 
VE-PTP Receptor-type tyrosine-protein phosphatase 
WB  Western blot 
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Units  
 
g Gram 
mg Milligram 
µg Microgram 
µL Microliter 
mL Milliliter 
L Liter 
M Molar 
mM Millimolar 
mol Mole 
µmol Micromole 
pmol Picomole 
mm Millimeter 
µm Micrometer 
m2 Square meter 
cm2 Square centimeter 
mm2 Square millimeter 
h Hour 
min Minute 
s Second 
v Volt 
U Unit 
KDa KiloDalton 
rpm Round per minute 
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1 Introduction  
1.1 Diabetes  
 
Diabetes is a metabolic disorder caused by hyperglycemia resulting from 
defects in insulin secretion and function. Long-term exposure to hyperglycemia 
leads to the dysfunction, failure, and damage of multiple organs, particularly 
kidneys, nerves, eyes, heart, and blood vessels (Association, 2010). Currently, 
the incidence of diabetes is growing at alarming rates worldwide. According to 
the 2013 report of the International Diabetes Federation (IDF), approximately 
382 million people had diabetes, and this number will reach 592 million by 2035 
based on investigations in 130 countries. This indicates that the number of 
people with diabetes will increase by 55% by 2035. As shown in Fig. 1, China 
contributes the most to the world population of patients with diabetes, which is 
approximately 98.4 million. India is in second place, with approximately 65.1 
million diabetic people. The prevalence of diabetes increases, especially in 
developing countries. Therefore, diabetes has already become a leading public 
health challenge and a significant economic burden worldwide (Guariguata et 
al., 2014a). 
 
 
Figure 1: Top ten countries showing the number of people with diabetes in 2013 
and 2035. Permission obtained from copyright © 2014 Elsevier Ireland Ltd (Guariguata 
et al., 2014b). 
 
1.2 Diabetic retinopathy 
 
Diabetic retinopathy (DR) is a diabetic complication that impairs the vision of 
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patients with diabetes, and is associated with vascular and neuronal damage, 
retinal edema, hemorrhage, and abnormal growth of new blood vessels 
(Abcouwer and Gardner, 2014). Clinical evidence reveals that DR affects nearly 
93 million people worldwide, approximately 28 million of whom are at the risk 
of developing vision loss (Pascolini and Mariotti, 2012; Sivaprasad et al., 2012; 
Yau et al., 2012). The World Health Organization (WHO) has predicted that 
approximately 15−17% cases of total blindness in Europe and the USA are due 
to DR (Resnikoff et al., 2004). Statistically, the data from epidemiological 
studies indicate that almost all patients with type 1 diabetes (T1D) will develop 
at least retinopathy after 20 years of diabetes. More importantly, retinopathy will 
occur in approximately 80% patients with insulin-dependent type 2 diabetes 
(T2D) and in 50% patients with insulin-independent T2D after 20 years of 
diabetes (Klein et al., 1989). Among patients with diabetes worldwide, 33% 
show overall prevalence of DR. Longer disease duration, higher hemoglobin 
A1C (HbA1c) level, and hypertension will increase the risk of DR (Yau et al., 
2012). Thus, DR is becoming an ever-increasing health burden and global 
problem.  
 
1.3 Retinal vasoregression  
 
DR has been consistently considered a microvascular disease. It is primarily 
classified into the early stage, which is non-proliferative DR, and the late stage, 
which is proliferative DR. Retinal vasoregression is a hallmark of early DR, 
which is characterized by initial retinal pericyte loss and subsequent formation 
of acellular capillaries (Fig. 2). Without the protection of pericytes, retinal 
endothelial cells are susceptible to ischemia, angiogenic factors, and 
inflammatory factor attack, which lead to endothelial cell death. Acellular 
capillary with no blood flow is formed after pericyte and endothelial 
disappearance. Retinal capillary occlusion induced by pericyte loss and 
subsequent endothelial cell death aggravates ischemia. In response to 
progressive capillary loss, vascular endothelial growth factor (VEGF) level is 
elevated, which results in the formation of newly abnormal vessels. The 
breakage of retinal vessel effortlessly induces retinal vascular leakage and 
bleeding, which impairs vision.  
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Figure 2: Retinal vasoregression in rats. (A) Normal retinal vasculature in rats. The 
red arrow indicates pericytes. The dark blue arrow indicates endothelial cells. (B) Rats 
with retinal vasoregression. Black arrow indicates acellular capillaries.  
 
1.4 Retinal neurovascular unit 
 
Pericytes belong to vascular mural cells that are located at the abluminal 
surface of the capillary. They closely communicate with endothelial cells and 
are embedded in the vascular basement membrane (Armulik et al., 2011; 
Shepro and Morel, 1993a). Pericytes are the major components of the retinal 
neurovascular unit (RNV). In the normal RNV, they combine with endothelial 
cells, microglial cells, astrocytes, Muller cells, and neuronal cells, and are 
crucial for blood-retina barrier (BRB) permeability, angiogenesis, cellular 
metabolism and neuroinflammation (Fig. 3) (Sweeney et al., 2016). The 
impairment of the RNV is involved in DR pathogenesis. Under diabetic 
conditions, all the components of RNV are disrupted by long-term exposure to 
hyperglycemia. Hyperglycemia causes retinal endothelial cell dysfunction by 
affecting mitochondria function, which increases oxidative stress and 
accelerates endothelial cell death (Davidson and Duchen, 2007). Retinal 
endothelial cells are the crucial elements for BRB, which is disrupted by chronic 
hyperglycemia exposure. The main contributors to BRB destruction are VEGF, 
proinflammatory cytokines, such as IL-1β, TNF-α, and IL-6, and monocyte 
chemoattractant protein-1 (MCP-1) (Tang and Kern, 2011). The reduced 
thickness of the nerve fiber layer and increased expression of Bax, caspase-3, 
and caspase-9 shows that the retinal ganglion cells are dead (Kern and Barber, 
2008). Retinal glial cells, such as Muller cells, are activated due to the 
upregulation of GFAP (Qiu et al., 2018). Microglial cells have immunological cell 
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functions. After exposure to hyperglycemic conditions, microglial cells are 
activated and can release several immunological cytokines and chemokines to 
aggravate retinal damage (Joussen et al., 2004). Chronic HG exposure disrupts 
the signaling pathway among retinal cells. As a result, increase in VEGF and 
Ang-2 expression are observed. The elevated Ang-2 level leads to pericyte loss 
and endothelial cell dysfunction, which ultimately induces vascular leakage. 
Severe retinal and vitreous bleeding can cause vision loss (Gardner and Davila, 
2017).  
 
Figure 3: Retinal neurovascular unit is composed of retinal endothelial cells, 
pericytes, astrocytes, Muller cells, and neuronal cells. Permission obtained from 
copyright © 2018 Macmillan Publishers Limited, part of Springer Nature (Santos et al., 
2018) 
 
1.4.1 Pericyte morphology and characterization 
 
Pericytes are specialized cells mainly present in the capillaries, which are 
derived from the neural crest during embryonic development (Etchevers et al., 
2001). French scientist Charles Rouget initially proposed the existence of 
pericytes in 1873 (Rouget, 1873), and they were named “pericytes” by 
Zimmermann in 1923 (Zimmermann, 1923). Similar to smooth muscle cells, 
pericytes possess contractile properties and regulate vascular tone (Hamilton 
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et al., 2010). In mature rodents, retinal capillary pericytes are associated with 
endothelial cells and astrocytes, and wrap around the capillary. In contrast to 
the elongated shape of the endothelial cell nucleus, pericytes have prominent 
round nuclei. Pericytes exhibit extended processes that cover the wall of blood 
vessels (Dore-Duffy and Cleary, 2011). The retina has the most abundant 
pericyte coverage. The ratio of pericyte to endothelial cells in the retina ranges 
from 1:1 to 1:3. In other tissues, such as the brain, lung, and skeletal muscle, 
this ratio is 1:5, 1:10, and 1:100, respectively (Frank et al., 1987; Frank et al., 
1990; Kuwabara and Cogan, 1963; Laties et al., 1979; Shepro and Morel, 
1993b). Pericytes can express several cell surface markers, including NG2, 
PDGFRβ, CD13, and CD146 (Gerhardt and Betsholtz, 2003; Murfee et al., 2005; 
Xu et al., 2013). In addition, pericytes also express contractile and cytoskeletal 
proteins such as α SMA, vimentin, desmin and nestin (Fujimoto and Singer, 
1987; Lardon et al., 2002; Morikawa et al., 2002).  
 
1.4.2 Pericyte function 
 
Retinal pericytes contribute to blood-retina barrier integrity, and are responsible 
for vessel maturation and stabilization, angiogenesis, and vascular remodeling. 
Dysfunction or loss of pericyte is linked to many diseases such as DR (Zlokovic, 
2011). Hammes et al. have demonstrated that pericyte loss is the first sign of 
early DR by quantifying pericyte coverage in a retinal capillary using retinal 
digestion preparation from rodent models. Pericyte loss subsequently induces 
retinal endothelial cell dysfunction, which further promotes acellular capillary 
formation and capillary occlusion, aggravating retinal ischemia and enhancing 
VEGF production (Hammes et al., 2011). Therefore, pericyte coverage is crucial 
for the stabilization of retinal vasculature. In addition to retinal disease, 
pericytes also play a critical role in Alzheimer-like neurodegeneration, as 
pericyte loss promotes the progressive pathology of Alzheimer's disease, such 
as increase in amyloid β-peptide content, tau pathology, and neuronal cell loss 
(Halliday et al., 2016; Sagare et al., 2013). Decreased pericyte coverage has 
also been observed in diseases, such as stroke, multiple sclerosis, brain tumor, 
and aging (Duz et al., 2007; Feng et al., 2008; Ho, 1985). Thus, pericyte can 
be a therapeutic target for retinal and neuronal degenerative disease.  
 
1.4.3 Pericyte-endothelial signal transduction 
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Pericytes connect to endothelial cells via adhesion junctions (AJs), tight 
junctions (TJs), and gap junctions (GJs). The signal pathways and molecules 
between endothelial cells and pericytes, including Ang/Tie-2, TGF-β signaling 
pathway, and PDGF-B/PDGFR-β play crucial roles in protecting vascular 
integrity (Fig. 4).  
 
 
Figure 4: Signaling pathway and junctional molecules between endothelial cells 
and pericytes in retinal capillary. Reprinted from an open access article distributed 
under the Creative Common Attribution License (ElAli et al., 2014). 
 
(1) Angiopoietin-Tie-2 signaling 
 
The Tie-2 receptor, a transmembrane tyrosine kinase highly expressed in the 
endothelium, is essential for the regulation of vascular barrier function in healthy 
and diseased states. It has two ligands Ang-1 and -2, which exert opposing 
effects on this receptor. Ang-1, mainly secreted by pericytes, preserves 
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vascular integrity, whereas Ang-2, an antagonist of Tie-2 expressed by 
endothelial cells, causes vascular destabilization and reduces pericyte 
coverage of the vasculature (von Tell et al., 2006). Ang-2 competes with Ang-1 
to bind to the Tie-2 receptor, which leads to phosphorylation of its tyrosine 
residue and destabilization of the interaction between endothelial cells and 
pericytes (Maisonpierre et al., 1997). A clinical study reported that compared to 
in diabetic patients without DR, the serum level of Ang-2 is significantly elevated 
in patients with DR (Khalaf et al., 2017). Intravitreally injected Ang-2 induces 
retinal pericyte loss and increases the formation of acellular capillaries in the 
eyes of healthy rats. Diabetes-induced pericyte loss and acellular capillary 
formation are rescued in heterozygous Ang-2 deficient mice (Hammes et al., 
2004). 
 
(2) TGF-β signaling 
 
TGF-β is a multifunctional cytokine that is widely expressed by endothelial cells 
and pericytes, and is involved in cellular proliferation and differentiation. TGF-β 
is required to sustain endothelial-pericyte interactions. Disruption of the TGF-β 
signaling pathway via ablation of its downstream molecule Smad4 leads to 
reduced pericyte coverage of capillaries and enhanced vascular permeability 
(Li et al., 2011; Winkler et al., 2011). TGF-β prevents vascular pericyte 
proliferation via the induction of VEGFR-1 in endothelial cells (Shih et al., 2003). 
Neuronal cadherin (N-cadherin), a vital adhesion junction, is enriched between 
pericytes and endothelial cells, and reduced N-cadherin expression is observed 
in DR (Hu et al., 2017). TGF-β signal transduction is essential for endothelial 
cell communication with pericytes. Activation of the TGF-β signaling pathway 
upregulates N cadherin (Ma et al., 2018). 
 
(3) PDGF-B/PDGFR-β signaling 
 
PDGF-B is predominantly expressed by retinal endothelial cells and binds to 
PDGFR-β, which is expressed by pericytes. PDGF-B/PDGFR-β signaling is 
vital for the recruitment of retinal pericytes. Pericyte-specific PDGF-B- and 
PDGFRB deficient mice display multitudinous broken microaneurysms. 
Perinatal death due to extensive microvascular leakage and bleeding are 
observed in PDGF-B and PDGFRB knockout mice (Leveen et al., 1994; Lindahl 
et al., 1997). PDGF-B depletion in endothelial cells results in pericyte deficiency 
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(Enge et al., 2002).  
 
1.4.4 Endothelial cell-cell junctions 
 
Endothelial cell junctions are generally classified into two main types: TJs and 
AJs (Fig. 5). They both provide essential adhesive contacts between 
neighboring endothelial cells, although these junctions are composed of 
different proteins. Structurally, within cells, TJs are localized most apically along 
cell plasma membranes and act as a fence to separate membrane proteins 
between apical and basolateral membranes. Each TJ is paired to and 
associated with another TJ on the cell membrane. AJs are composed of 
cadherin family members of adhesion proteins found at the cell-cell junction of 
epithelial and endothelial cells, which are connected to the actin cytoskeletal 
proteins of adjacent cells. Cadherins regulate intracellular adhesion via Ca2+-
dependent and homophilic trans-interactions. Within endothelial cells, they 
dominantly express two types of cadherin: VE-cadherin and N-cadherin. N-
cadherin is also expressed in neural cells and smooth muscle cells. Other 
cadherins, for example, T-cadherin and P-cadherin, are variously expressed in 
distinct types of endothelial cells (Zhou et al., 2003).  
 
 
Figure 5: Schematic overview of adhesion junctions and tight junctions. α-cat: α-
catenin; β-cat: β-catenin; p120: p120 catenin; ZO: zona occludens. Reprinted from an 
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open access article distributed under the Creative Commons Attribution License (Sato 
and Coburn, 2017). 
 
1.4.4.1 VE-cadherin structure 
 
VE-cadherin, an endothelial-specific AJ, is the most studied molecule in the 
cadherin family, which plays a crucial role in endothelial barrier function and 
maintenance of vascular integrity. It is a transmembrane protein, including an 
extracellular domain that consists of five homologous repeats from EC1 to EC2 
(Fig. 6) and a cytoplasmic tail that associates with p120-catenin, β-catenin, and 
plakoglobin. Structurally, β-catenin binds to the carboxyl-terminal tail of 
cadherin, whereas p120-catenin binds to the juxtamembrane domain (JMD) of 
cadherin and modulates cadherin turnover (Cadwell et al., 2016). β-Catenin 
and plakoglobin directly bind to α-catenin, thereby regulating several 
cytoskeletal proteins such as actin and zonula occludens-1 (ZO-1). In addition, 
VE-cadherin also interacts with Src kinase and junctional phosphates (DEP-1 
and VE-PTP) (Wallez et al., 2006). Therefore, VE-cadherin directly or indirectly 
contributes to the intracellular signaling pathways that regulate endothelial cell 
motility, vascular genesis, angiogenesis, maintenance of cell-cell adhesion, 
actin protein remodeling, and gene transcription (Corada et al., 1999). Retinal 
VE-cadherin expression is significantly reduced in patients with diabetes. HG 
can activate matrix metallopeptidases (MMP) 2 and 9, which results in VE-
cadherin degradation (Navaratna et al., 2007). Endothelial cells exposed to HG 
show increased intracellular fiber contraction, which leads to loss of cell 
connection, disruption of VE-cadherin signals and reduction in VE-cadherin 
expression (Nobe et al., 2006; Wu et al., 2017).  
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Figure 6: The structure of VE-cadherin. Permission obtained from copyright © 2008 
The Company of Biologists Ltd (Dejana et al., 2008). 
 
1.4.4.2 VE-cadherin endocytosis and degradation 
 
Cellular interactions mediated by VE-cadherin are crucial for normal vascular 
morphogenesis. In the diseased state, such as cancer, inflammation, 
microvascular disorders, diabetes, and autoimmune diseases, VE-cadherin 
expression is often dysregulated (Reynolds and Carnahan, 2004). VE-cadherin 
is a highly dynamic adhesion junction protein that is transported into the cytosol 
via vesicle molecules. VE-cadherin endocytosis is mainly mediated via clathrin-
dependent and clathrin-independent pathways (Fig. 7) (Delva and Kowalczyk, 
2009). In the quiescent state, VE-cadherin interacts with p120-catenin and β-
catenin to protect the plasma membrane from VE-cadherin internalization into 
the cytosol via the formation of p120-catenin and small GTPase (Rho A, Rac 
and CDC42) complex (Xiao et al., 2007). Dissociation of the p120-catenin-VE-
cadherin complex after knocking down of p120-catenin promotes VE-cadherin 
internalization (Garrett et al., 2017). Without p120-catenin, VE-cadherin is 
degraded via the endo-lysosomal degradation pathway (Elia et al., 2006). A 
study has shown that presenilin-1 competes with p120-catenin for binding to 
VE-cadherin, which facilitates VE-cadherin endocytosis and degradation (Baki 
et al., 2001). Furthermore, ubiquitination also assists in the degradation of VE-
cadherin. For example, E3 ligase, also known as Hakai, is a c-Cbl-like protein, 
which ubiquitinates VE-cadherin (Fujita et al., 2002). The K5 ubiquitin ligase 
directly acts on VE-cadherin, which can drive VE-cadherin endocytosis and 
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degradation without a constitutive endocytic motif (Nanes et al., 2017). 
Endocytic adaptors, including adaptor 2 (AP-2), can bind to clathrin and 
phospholipids at the plasma membrane. Studies have shown that AP-2 
interacts with VE-cadherin and is involved in VE-cadherin endocytosis and 
degradation (Miyashita and Ozawa, 2007).  
 
 
Figure 7: Overview of VE-cadherin trafficking. VE-cadherin is expressed at the cell 
plasma membrane and interacts with p120-catenin and β-catenin via binding to the 
cadherin juxtamembrane domain (JMD) and catenin binding domain (CBD). VE-
cadherin internalization is regulated via clathrin-dependent and clathrin-independent 
pathways. Internalized VE-cadherin is degraded in the lysosome or returns to the 
plasma membrane. Permission obtained from copyright © 2007 Elsevier B. V. (Xiao et 
al., 2007). 
 
1.4.4.3 VE-cadherin phosphorylation 
 
It is well-known that the phosphorylation of VE-cadherin is associated with weak 
junctions and vascular permeability. The sites of tyrosine or serine 
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phosphorylation in the cytoplasmic tail of VE-cadherin are shown in Fig. 8. 
VEGF can phosphorylate VE-cadherin Tyr 658 and Tyr 685 via Src activation 
(Adam, 2015; Wallez et al., 2007). Leukocytes or lymphocytes also affect VE-
cadherin phosphorylation via multiple signaling pathways. VEGF can also 
regulate the process of VE-cadherin endocytosis. As shown in Fig. 9, VEGF 
triggers the phosphorylation of VEGFR2, Src kinase, and VE-cadherin (Tyr 685) 
at endothelial junctions, accompanying the generation of reactive oxygen 
species (ROS). Once VE-cadherin is phosphorylated, p120- and β- catenin 
dissociate from the VE-cadherin complex, promoting plasma membrane VE-
cadherin translocation toward the nucleus. In contrast, the disconnection of 
p120-catenin from VE-cadherin promotes VE-cadherin endocytosis via the 
clathrin-dependent pathway and accelerates VE-cadherin capture by 
lysosomes for degradation (Mukherjee et al., 2006). Once VE-cadherin is 
internalized into the cytosol, some regulatory proteins such as Hrs, Rab 5, and 
Rab 7 GTPase mediate the transport of the internalized VE-cadherin to the 
lysosome (Ogata et al., 2007; Palacios et al., 2005). Reports have shown that 
VE-cadherin tyrosine phosphorylation (Tyr 658 and Tyr 731) is involved in the 
induction of vascular permeability and leukocyte transmigration. As a result, 
increased VE-cadherin phosphorylation leads to gap enlargement between 
endothelial cells, thereby enhancing vascular permeability (Wessel et al., 2014). 
Other studies have reported that HG promotes VE-cadherin tyrosine 
phosphorylation (Tyr731) and Src kinase tyrosine phosphorylation (Tyr 416) via 
activation of PKC in endothelial cells. HG induces the separation of the VE-
cadherin/β-catenin complex and increases β-catenin translocation to the 
nucleus (Haidari et al., 2014). The mechanism underlying HG-induced VE-
cadherin degradation probably involves increased expression of presenilin-1 
(Nagai et al., 2016). The disruption of VE-cadherin internalization might weaken 
endothelial cell integrity (Gavard, 2014).  
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Figure 8: Phosphorylation site of VE-cadherin. Permission obtained from copyright 
© 2008 The Company of Biologists Ltd (Dejana et al., 2008). 
 
 
Figure 9: VEGF-mediated VE-cadherin endocytosis and degradation. Permission 
obtained from copyright © 2006 Wolters Kluwer Health, Inc (Mukherjee et al., 2006). 
 
1.5 The potential mechanism of pericyte loss in retinopathy 
 
Several factors are involved in pericyte loss during the early phase of DR, 
including HG insult, inflammation, and disruption of endothelial cell-pericyte 
interaction. Pericytes exposed to HG condition exhibit rapid accumulation of 
glucose in the cytosol with increased activity of AR (Akagi et al., 1983). HG 
causes mitochondrial dysfunction, such as decreased membrane potential, 
reduced oxygen consumption, and extracellular acidification, as well as 
enhanced mitochondrial fragmentation in retinal pericytes (Trudeau et al., 2011). 
The NF-κB signaling pathway in retinal pericytes is activated upon treatment 
with HG, which leads to cell apoptosis with increased expression of Bax and 
TNF-α (Romeo et al., 2002). HG reduces the connexin 43 (Cx43) gap junction 
expression in pericytes and loosens contact between pericytes (Li et al., 2003). 
Excessive glucose can produce more advanced glycation end products (AGEs) 
that are toxic to retinal pericytes. High level of AGEs increases Ang-2 
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expression, which causes pericyte loss via α3β4 integrin and p53 signaling 
pathways (Park et al., 2014). The increase in HG-induced oxidative stress also 
involves pericyte loss via the upregulation of pro-apoptotic thioredoxin 
interacting protein (Devi et al., 2013). Pericytes cultured under HG condition 
express high levels of IL-1β, TNF-α, and ICAM-1 (Nehmé and Edelman, 2008).  
 
1.6 Rodent retinopathy models 
 
Studying the pathogenesis of pericyte loss in retinal disease using human 
patient samples is challenging. Therefore, established animal models are 
proper tools for mimicking the complications of diseases and for uncovering the 
underlying mechanism. Among animal models, rodents are used most 
commonly for early retinopathy research.  
 
1.6.1 Ins2Akita mouse 
 
Ins2Akita mouse is one of the common models for the early phase of DR, which 
harbors a mutation in the insulin gene, resulting in destruction of pancreatic β 
cells and inability to produce adequate insulin. Ins2Akita mice are models for type 
1-diabetes, as they develop hyperglycemia in as early as four weeks. 
Furthermore, Ins2Akita mice produce high levels of active caspase-3, which 
leads to retinal cell apoptosis. After 12 weeks of hyperglycemia, Ins2Akita mice 
display retinal vascular permeability. Pericyte loss and acellular capillary 
formation occur after 36 weeks of hyperglycemia (Barber et al., 2005; Freeman 
et al., 2009). Three-month old Ins2Akita mice show retinal ganglion cell loss from 
the peripheral retina and abnormal morphological changes in retinal ganglion 
cells (Gastinger et al., 2008). Another study has reported that retinal thickness 
and vasculature do not change within six months in Ins2Akita mice. However, 
increased GFAP expression in Muller cells and reduced GFAP expression in 
astrocytes are observed in Ins2Akita mice (McLenachan et al., 2013). Five- and 
7.5-month old Ins2Akita mice exhibit deficiency in contrast sensitivity of 
optomotor behavior and spatial frequency threshold (Akimov and Rentería, 
2012). Furthermore, compared to that in age-matched control mice, the retinal 
microvasculature of 6-month old Ins2Akita mice displays reduced erythrocyte 
velocity, shear rate, and flow rate, as well as transient capillary inflow stoppage 
(Wright et al., 2012). Older Ins2Akita mice, such as 9-month old mice, showed 
defect in synaptic connectivity in the outer plexiform layer and reduction in the 
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number of retinal ganglion cells and amacrine cells (Hombrebueno et al., 2014). 
In Ins2Akita mice, formation of new abnormal vessels is accompanied by reduced 
retinal function until 9 months of age (Han et al., 2013).   
 
1.6.2 Rats with polycystic kidney disease 
 
Rats with polycystic kidney disease (PKD) express a truncated human 
polycystic-2 protein, which is predominantly located at the cilium, such as in 
kidney tubular epithelial cells and retinal photoreceptors. This mutation leads to 
the loss of almost the entire C-terminus of the protein. PKD rats are used to 
mimic the phenotype of autosomal dominant PKD, which often occurs in human 
patients. Polycystic-2 is essential for ion channel functions for maintenance of 
osmotic homeostasis (Liu et al., 2018). Before polycystic formation in the kidney, 
these rats develop retinal photoreceptor degeneration as an initial impairment 
at 1 month of age. Starting from the second month to the seventh month, PKD 
rats develop pericyte and endothelial cell loss and show retinal vascular 
regression as the secondary damage. Retinal vascular regression in PKD rats 
progresses over time. PKD rats also display microglia activation, such as 
upregulation of GFAP expression after one month, along with the increase in 
the expression of several neurotrophic factors, including FGF2, CTNF, and NGF 
(Feng et al., 2011; Feng et al., 2009; Gallagher et al., 2006). Muller cells in PKD 
rats show upregulation of AQP1 and AQP4, reduced Kir channel-mediated 
potassium conductance, and abnormal distribution of Kir4.1 protein, which 
contributes to retinal photoreceptor death (Vogler et al., 2013). Muller cells in 
PKD rats exposed to hypoosmotic conditions swell immediately. This effect is 
attributed to the induction of oxidative and nitrosative stress, mitochondrial 
dysfunction, and increased expression of inflammatory lipid mediators (Vogler 
et al., 2016). PKD rats can be considered as an animal model for retinal 
vascular regression induced by neurodegeneration without hyperglycemia.  
 
1.6.3 Nucleoside diphosphate kinase B knockout mouse 
1.6.3.1 The NDPK family  
 
NDPKs, encoded by the NME genes, are ubiquitous enzymes that catalyze the 
exchange of phosphate between nucleoside diphosphates (NDP) and 
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triphosphate (NTP) reversibly, which involve the generation of a high energy 
phosphate intermediate (Abu-Taha et al., 2018; Wieland, 2007) (Fig. 10). They 
were identified in the 1950s in the yeast and pigeon breast muscle and exist as 
ten isoforms (Berg and Joklik, 1953; Krebs and Hems, 1953). Based on their 
catalytic activity and sequence homologies, the isoforms are classified into two 
classes. NDPK A, B, C, and D belong to class I, whereas the rest of the NDPK 
isoforms belong to class II (Wieland, 2007). In class I, the isoforms are 
catalytically active and share 58--88% sequence homology. The isoforms in 
class II share only 25--45% homology (Gilles et al., 1991). Most of the genes in 
class II are primarily expressed in primary cilia and sperm flagella (Boissan et 
al., 2009). In mammalian cells, the isoforms form heterohexamers of 17--21 
kDa.(Gilles et al., 1991; Janin et al., 2000). NDPKs are multifunctional proteins 
that are involved in tumor metastasis, cell development, gene regulation, 
apoptosis, and endocytosis (Fan et al., 2003; Krishnan et al., 2001; Postel, 
2003; Rosengard et al., 1989; Steeg et al., 1988). Till now, NDPK A and B are 
the most studied isoforms.  
 
Figure 10：The reaction mechanism catalyzed by NDPK. Permission obtained from 
copyright © 2018 Springer Nature (Attwood and Muimo, 2018).  
 
1.6.3.2 NDPKs and G-protein activation 
 
G proteins were first identified by Alfred G. Gilman and Martin Rodbell when 
they stimulated cells with adrenaline (Gilman, 1989). G protein-coupled 
receptors (GPCR) primarily dominate the activity of heterotrimeric G proteins 
(Gαβγ), which participate in cellular signal transduction. G protein contains two 
functional units: Gα and Gβγ dimers (Hamm, 1998). Gα is tightly associated with 
Gβγ dimers in the internal surface of the cell membrane. In the inactive state, 
GDP binds to the Gα unit. However, upon ligand-induced GPCR activation, GDP 
is released from Gα, which in turn binds to GTP, causing the dissociation of the 
Gα unit from Gβγ dimers (Wall et al., 1995). Reports show that NDPK B interacts 
with Gβγ, which is essential for G protein function. As shown in Fig. 11, NDPK 
B can utilize NTP, preferably ATP, to form GTP. NDPK B triggers its 
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autophosphorylation on His118 site and subsequently phosphorylates the 
His266 site of Gβ to mediate GPCR-independent G protein activation (Mäurer 
et al., 2005).  
 
 
 
 
Figure 11: GPCR-dependent and alternative NDPK B dependent G protein 
activation. Permission obtained from copyright © 2007 Springer Nature (Wieland, 
2007).  
 
1.6.3.3 NDPKs and endocytosis 
 
NDPKs interact with dynamin, which is the crucial mediator of the actin 
cytoskeleton. Three isoforms of dynamin have been identified in mammals, 
namely dynamin 1, 2, and 3. Among these, dynamin 2 is widely expressed in 
mammalian cells, whereas dynamin 1 and 3 are mostly presented in the brain. 
Dynamin 2 is primarily involved in cellular endocytosis (Ferguson and De 
Camilli, 2012; Menon and Schafer, 2013). Early studies have reported that 
NDPKs contribute to dynamin-mediated endocytosis of E-cadherin, which leads 
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to the loss of adhesion junctions (Palacios et al., 2002). The loss of NDPK B 
results in the inhibition of endocytosis and accumulation of clathrin-coated pits 
(Snider et al., 2015). Another study has reported that an intimate connection 
between NDPK B and caveolin proteins is key for caveolae formation, which is 
a participant in vesicle trafficking and endocytosis (Hippe et al., 2011).  
 
1.6.3.4 NDPKs and diabetes 
 
The Goto-Kakizaki rat model, which is a type 2 diabetic model, exhibits 
approximately 50% reduction in NDPK activity, histidine kinase activity, and 
autophosphorylation activity (Kowluru, 2003; Metz et al., 1999). The G protein 
activation mediated by NDPK B/Gβγ complexes is perturbed in the pancreatic β 
cells of diabetic animals (Kowluru et al., 2011). The loss of NDPK B induces 
diabetes-like vascular damage via increased expression of endothelial Ang-2 in 
the retina (Qiu et al., 2016). O-GlcNAc of FoxO1 mediates NDPK B deficiency-
induced Ang-2 elevation and endothelial damage (Shan et al., 2018). Ang2 
upregulation is harmful for endothelial-pericyte interaction (Maisonpierre et al., 
1997; Yuan et al., 2009). NDPK B also contributes to vascular integrity. NDPK 
B deficiency displays vascular hyperpermeability and disrupts adhesion 
junctions between endothelial cells. NDPK B depletion affects VEGF-induced 
sprouting (Feng et al., 2014). In addition, NDPK B depletion in zebrafish causes 
a defect in cardiac contractility in conjunction with the downregulation of 
caveolin-1, caveolin-3, and Gβ1γ2 (Hippe et al., 2009). NDPK B is believed to 
act as histidine kinase that can phosphorylate intermediate conductance 
potassium channels, including the KCa3.1 channel and Ca2+-conducting TRP 
channel family member 5 (TRPV5).  
 
1.7 Mesenchymal stem cells  
 
Mesenchymal stem cells (MSCs) were first recognized and described in bone 
marrow by Friedenstein and his colleagues in the 1970s (Owen and 
Friedenstein, 1988). These cells can be distinguished from hematopoietic stem 
cells (HSCs) by their fast adherence to vessels, fibroblast-like morphology, and 
strong proliferative ability (Caplan, 1991). MSCs reside in the perivascular 
niches where they can sustain self-renewal and preserve the surrounding cells 
and tissues. MSCs belong to multipotent stem cells derived from developed 
organs, including bone marrow, adipose, skeletal muscle, dental tissue, 
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placenta, and umbilical cord, which are capable of differentiating into a variety 
of cell types including osteoblasts, myocytes, chondrocytes, and adipocytes 
(Fig. 12) (Bianco et al., 2008; Busser et al., 2015; De Bari et al., 2003; Huang 
et al., 2009; Mackay et al., 1998; Sibov et al., 2012; Vellasamy et al., 2012). In 
some tissues, MSCs share markers with pericytes such as NG2 and PDGFRβ 
(Feng et al., 2010). Till date, various studies have shown that pericytes can 
differentiate into chondrocytes, adipocytes, and phagocytes, which strongly 
suggests that pericytes are similar to MSCs in terms of cell differentiation 
(Hirschi and D'Amore, 1996; Paquet-Fifield et al., 2009; Richardson et al., 
1982). Owing to multiple differentiation properties and similarities with pericytes, 
MSCs possess enormous potential for the treatment of degenerative diseases 
such as DR. Indeed, MSCs are the ideal candidates for treating DR as they can 
replace the damaged pericytes, promote pericyte coverage in retinal capillary 
vasculature, and stabilize retinal vasculature, and mitigate vascular leakage 
(Ding et al., 2017; Fiori et al., 2018).   
 
 
Figure 12: Multipotency of MSCs. MSCs reside in the perivascular niches and have 
multiple differentiation properties. They maintain cells and tissues. Under special 
conditions, they can differentiate into osteocytes, endothelial cells, chondrocytes, 
adipocytes, odontoblasts, and neurons. Reprinted from an open access article 
distributed under the Creative Commons Attribution License (Oh and Nör, 2015).  
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1.8 Therapeutic effects of MSCs in retinal degenerative 
diseases 
Till now, most investigations on stem cells have focused on preclinical studies 
using different animal models with retinal disorders such as DR. Current 
therapeutic strategies for retinal degenerative diseases using MSC-based 
therapy involve: 1) MSC replacement in the injured retinas; 2) manipulation of 
paracrine secretion properties of MSC for preserving retinal damaged cells and 
restoring retinal cell functions (Fig. 13).  
 
1.8.1 MSC plasticity 
 
An early study by Kicic et al. in 2003 has demonstrated that MSCs differentiate 
into retinal photoreceptor cells when exposed to activin A, epidermal growth 
factor (EGF), and taurine in vitro. More importantly, they also provided evidence 
that MSCs injected in the subretinal region of a rat model with retinal 
degeneration can migrate into the photoreceptor layer and express 
photoreceptor markers in vivo without any adverse effects (Kicic et al., 2003). 
Another report has revealed that the trabecular meshwork- and conjunctiva-
derived MSCs can transform into photoreceptor-like cells in vitro (Nadri et al., 
2013a; Nadri et al., 2013b). Similarly, another study has shown that bone 
marrow-derived MSCs (BMSCs) can differentiate into retinal neuronal cells in 
injured rats (Tomita et al., 2002). Adipose-derived MSCs (ASCs) cultured in 
retinal pigment epithelium (RPE) -conditioned medium with vasoactive 
intestinal peptide display RPE features and markers (Vossmerbaeumer et al., 
2009). Mendel et al. (2013) have reported that ASCs can differentiate into 
pericytes after treatment with TGF-β (Mendel et al., 2013). Furthermore, 
BMSCs have been reported to differentiate into neural precursor cells and 
mature neurons when treated with neural selection and induction medium 
(Chiou et al., 2005). Chakravarathy et al. have shown that BMSCs can migrate 
to diabetic mouse retina and express microglial, endothelial, pericyte, and 
Muller cell markers (Chakravarthy et al., 2016). Catanheira et al. have 
demonstrated that MSCs injected intravitreally migrate to and are incorporated 
into the retinal outer nuclear layer in the injured retina of rats. They are even 
present in the subretinal space. Most of the transplanted cells can express the 
markers for amacrine cells, bipolar cells, and retinal rod photoreceptor, whereas 
a few graft cells can express glial cell markers but not retinal pigment epithelial 
24 
 
cell markers (Castanheira et al., 2008). These results strongly indicate the 
potential of MSC-based cell therapy for retinal degenerative disease.  
 
1.8.2 Paracrine signaling  
 
MSCs can mitigate vascular and neuronal damage via the upregulation of 
several cytoprotective and neurotrophic factors in DR or retinal degenerative 
diseases. Otani et al. have reported that intravitreally injected MSCs preserve 
retinal blood vessels and rescue retinal degeneration in rd1 and rd10 mouse 
models (retinal degeneration models) via upregulation of antiapoptotic factors 
(Otani et al., 2004). Thomas et al. have reported that ASCs can differentiate 
into pericyte-like cells and migrate into retinas in the model of retinopathy of 
prematurity (ROP), preventing progressive degeneration of the retinal capillary 
network (Mendel et al., 2013). Yang et al. demonstrated that MSC 
transplantation reduces blood glucose level and promotes vascular leakage 
repair in streptozotocin-induced diabetic rats (Yang et al., 2010). A recent study 
has demonstrated that intravitreal injection of both ASCs or primed condition 
medium from stem cells exert a protective role in Ins2Akita mice, including 
reduced retinal GFAP expression and retinal vascular hyperpermeability 
(Elshaer et al., 2018). Intravitreal injection of BMSCs contributes to the survival 
of retinal ganglion cells in the ischemia/reperfusion injury rat models (Na et al., 
2009). In an ocular hypertension model, BMSCs produce neurotrophic factors 
to reduce retinal ganglion cell death (Johnson et al., 2010a). Subretinal 
transplantation of BMSCs promotes retinal photoreceptor survival and delay 
their death in the Royal College of Surgeons (RCS) rats (Inoue et al., 2007).  
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Figure 13: Strategy of MSC-based therapy for DR. MSCs replace the injured 
pericytes after intravitreal administration. MSCs preserve retinal vascular integrity and 
promote neurodegenerative repair via paracrine signaling. Reprinted from open 
access article distributed under the Creative Commons Attribution License 
(Rajashekhar, 2014).  
 
1.9   Aims of this study 
Retinal vasoregression involves pericyte loss and formation of acellular 
capillary. It is a hallmark of early retinopathy. Retinal pericytes support 
endothelial cells, control endothelial cell proliferation, and play a vital role in the 
retinal neurovascular unit. Retinal vascular destabilization, such as dysfunction 
of endothelial cells, leads to breakdown of the blood-retina barrier, which 
causes retinal edema and bleeding as well as vision loss. Among the adhesion 
junction molecules, VE-cadherin is essential for endothelial barrier function and 
vascular stability. Dysregulation of VE-cadherin, such as downregulation of VE-
cadherin or increased phosphorylation of VE-cadherin, impairs barrier functions. 
Adequate pericyte coverage and VE-cadherin expression facilitate vascular 
integrity.  
 
We have previously reported that PKD rats, NDPK B-/- mice, and Ins2Akita mice 
are three different animal models of retinal vasoregression. PKD rats progress 
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to pericyte loss at 2 months, which is associated with retinal photoreceptor 
degeneration. NDPK B-/- mice exhibit diabetes-like vascular pathology such as 
retinal pericyte loss at 5 months. Ins2Akita mice display retinal vasoregression at 
3 months. Nevertheless, whether these retinopathy models show abnormal 
expression of VE-cadherin in retinas and whether the disrupted VE-cadherin 
expression affects pericyte stability are still unknown.  
 
On the other hand, from a clinical perspective, MSC-based therapy may be 
used for treating retinal degenerative disorders. MSCs have multipotent 
functions. For example, they differentiate into pericytes that can rapidly attach 
to the vessels and migrate to the retinal pericyte position. In addition, they can 
produce several trophic factors to nourish and repair impaired retinal vessels 
and protect pericytes and endothelial cells from damage. However, the specific 
mechanism via which MSCs migrate into the retina, differentiate into pericytes, 
and repair injured retinal cells in vivo is still uncertain. Based on the data on 
retinal vasoregression and the role of VE-cadherin in the neurovascular unit 
from our group and those of others, as well as the features shared between 
MSCs and pericytes, we aimed to investigate the following:  
1. a) the characteristic phenotype of retinal VE-cadherin expression in these 
animal models of retinal vasoregression with and without hyperglycemia; 
b) the link between VE-cadherin dysregulation and pericyte loss; c) the 
signal transduction in VE-cadherin-mediated vasoregression. 
 
2. a) whether intravitreal injection of MSCs or MSC secretion can restore 
pericyte coverage, reduce the formation of acellular capillary and improve 
the retinal neuronal functions in vasoregressive retinas; b) whether 
intravitreally injected MSCs can migrate into retinas, integrate with retinal 
vessels and differentiate into pericyte-like cells in vivo; c) the underlying 
mechanism of action of intravitreally injected MSCs in retinal 
vasoregression. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Animals 
NDPK B-/- mice, Ins2Akita mice, Sprague Dawley (SD) rats, and PKD rats were 
used in the experiments. Animal care and experimental procedures were 
performed per the guidelines of the Association for Research in Vision and 
Ophthalmology (ARVO) and were approved by the local government.  
2.1.2 Cells 
Human ASCs and rat BMSCs isolated from adult SD rats were obtained from 
the laboratory of Prof. Karen Bieback (Institute for Transfusion medicine and 
Immunology, Medical Faculty of Mannheim, Heidelberg University). Human 
umbilical cord vein endothelial cells (HUVECs) were isolated from the umbilical 
cords of healthy pregnant women with informed consent. Rat fat pad endothelial 
cells (RFPECs) were used for intravitreal injection, and human brain pericytes 
were used for endothelial-pericyte co-culture experiments. The right eyes of 
rats were intravitreally injected with cells [20,000 in 2 µL phosphate buffered 
saline (PBS)], including human ASCs or starved BMSCs, using serum-free 
medium, or non-starved BMSCs, or HUVECs, or RFPECs, while PBS was 
administered in the left eyes as control.  
 
2.1.3 Chemical materials 
Table 1: chemicals and reagent 
Chemicals and reagents Company  
4',6-diamidino-2-phenylindole (DAPI) Sigma-Aldrich 
4% PFA Merck 
10× PBS Thermo Fisher Scientific 
Bovine serum albumin (BSA) Sigma-Aldrich 
D-glucose Sigma-Aldrich 
Difco Trypsin 250 BD Bioscience 
DMSO Sigma-Aldrich 
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DRAQ5 Cell Signaling Technology 
Ethanol absolute Fischer 
Isoflurane “Forene 100%.” Abbott 
L-glucose Sigma-Aldrich 
Mayer’s Hemalum solution Merck 
Methonal Sigma-Aldrich 
Roti®-Mount FluorCare Carl Roth 
Novesine@ 0.4% eye drop OmniVision 
Nuclease free water Promega 
Periodic acid Sigma-Aldrich 
PP2 Santa Cruz Biotechnology 
Schiff’s reagent Merck 
Sucrose Sigma-Aldrich 
TaqMan Fast Advanced Master Mix Thermo Fisher Scientific 
Tris Carl Roth 
Tris-HCl Carl Roth 
Triton X-100 Carl Roth 
Trypsin Merck 
Tween 20 Sigma-Aldrich 
O.C.T compound  Sakura Finetek 
 
2.1.4 Cell culture medium and substances  
Table 2: cell culture media and substances 
Media and substances Company 
Endothelial cell medium  Promocell 
Dulbecco’s modified eagle medium 
(DMEM) with 1000mg/L glucose 
Sigma-Aldrich & Lonza 
MCDB 131 medium Thermo Fisher Scientific 
EDTA-Trypsin 0.05% Sigma-Aldrich 
Fetal calf serum (FCS) GE Healthcare 
L-Glutamine 200 mM Sigma-Aldrich 
SD rat serum  Innovative Research 
Phosphate-buffered saline (PBS) Sigma-Aldrich 
Penicillin 100 U- Streptomycin 10 
mg/mL 
Sigma-Aldrich 
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2.1.5 siRNA 
Table 3：siRNA 
siRNA Sequence 
Control-siRNA  5’-AACUGGUUGACUACAAGUCUU-3’ 
NDPK B-siRNA 5’-AGGUAGUGUAAUCGCCUUG-3’ 
VE-cadherin siRNA 5’-ACCACGAAACGTGAAGTTCAA-3’ 
 
2.1.6 Buffers 
Table 4: Buffers for immunohistochemistry  
Buffer Contents 
Antigen retrieval buffer Solution A: 
2.1 g citric acid monohydrate to 100 mL ddH2O 
→ pH 6.0-6.3 
Solution B: 
3.6 g trisodium citrate dihydrate to 100 mL ddH2O 
→ pH 6.0-6.3 
Working solution: 
1.48 mL A + 2.504 mL B to 400 mL ddH2O 
Fixation buffer 4% PFA in PBS 
Blocking/permeabilization buffer 2.5% BSA, 0.3% Triton in PBS 
Antibody diluting buffer 1% BSA, 0.3% Triton in PBS 
Wash buffer  1× PBS 
 
Table 5: Buffers for immunocytochemistry  
Buffer Contents 
Fixation buffer 4% PFA in PBS 
Blocking/permeabilization buffer 1% BSA, 0.3% Triton in PBS 
Antibody diluting buffer 1% BSA, 0.3% Triton in PBS 
Wash buffer  1× PBS 
 
Table 6: Buffers for retinal digestion 
Buffer Contents 
Fixation buffer  4% Formalin  
Wash buffer  1× PBS 
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Retinal digestion buffer 3% Trypsin-Tris  
 
Table 7: Buffers for retinal whole-mount staining 
Buffer Contents 
Fixation buffer  4% Formalin  
Wash buffer  1× PBS/0.1% Triton in PBS 
Blocking/permeabilization buffer 1% BSA and 0.2% Triton in PBS  
 
Table 8: Buffers for immunoblotting 
Buffer Contents 
RIPA buffer 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM 
dithiothreitol, 1% Triton X-100, 1% sodium 
deoxycholate 
Protein loading buffer 25 mL 50% glycerol 
5 mL 10% 2-mercaptoethanol 
7.5% SDS; 15 mL 300 mM Tris, pH 6.8 
0.25% Bromophenol Blue; 5 mL H2O 
Cell lysis buffer 10 mL RIPA buffer with one tablet proteinase 
cocktail inhibitor 
TBS (10x) 100 mM Tris pH: 7.4; 1.5 M NaCl 
TBST (1 L) 100 mL TBS (10×), 890 mL H2O; 10 mL 10% 
Tween 20 
SDS-PAGE electrophoresis buffer 0.125 M Tris; 1.25 M glycine; 0.5% SDS 
Tris buffer (stacking gel) 1 M Tris pH: 6.8 
Tris buffer (separating gel) 1.5 M Tris pH: 8.8 
Western blot buffer (10x) (1L) 32.5 g Tris; 144 g glycine; 1 L H2O 
Transferring buffer (1 L) 100 mL western blot buffer (10x); 200 mL 
Methanol; 700 mL H2O 
Ponceau S (100 mL) 5 mL acetic acid; 95 mL H2O; 0.2 g Ponceau S 
 
2.1.7 Antibody 
Table 9：Antibodies for FACs 
Antibody Cat. Nr. Company 
CD44-APC Clone 12K35 LifeSpan BioSciences 
CD45-FITC Clone OX-1 BioRad 
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CD90-PE Clone OX-7 Becton Dickinson 
Table 10：Primary Antibodies  
Antibody Cat. Nr. Company 
GFAP Z0334 Dako 
 sc-6170 Santa Cruz Biotechnology 
HSP27 
HSP90 
sc-1048 
4874 
Santa Cruz Biotechnology 
Cell Signaling Technology 
GS MAB302 Merck 
IL-1β AF-501-NA R&D Systems 
Iba1 019-19741 Wako Chemicals 
Lectin  L5264 Sigma-Aldrich 
VE-cadherin AF1002 R&D Systems 
 ALX-803-305-
C100 
Enzo Life Science 
β catenin sc-7199 Santa Cruz Biotechnology 
p120 catenin sc-1101 Santa Cruz Biotechnology 
NDPK B  MC-412 Kamiya Biomedical Company 
Gβ Sc-378 Santa Cruz Biotechnology 
Phospho-VE-cadherin 
(Y685) 
Ab119785 Abcam 
Phospho-src (Y416) 2101 Cell Signaling Technology 
src 2108 Cell Signaling Technology 
γ-Tubulin T5168 Sigma-Aldrich 
 
Table 11：Secondary Antibodies  
Antibody Cat. Nr. Company 
Rabbit anti-mouse peroxidase A-9044 Sigma-Aldrich 
Rabbit anti-goat peroxidase A-8919 Sigma-Aldrich 
Goat anti-rabbit peroxidase 
Alexa Fluor 633 conjugate 
A-9169 
A-21052 
Sigma-Aldrich 
Life Technologies 
Alexa Fluor 555 conjugate A-32727 Life Technologies 
Alexa Fluor 594 conjugate  115-585-044 Jackson 
ImmunoResearch 
Alexa Fluor 488 conjugate A-11001 Life Technologies 
Swine anti-rabbit FITC  F0205 Dako 
Swine anti-rabbit TRITC R0156 Dako 
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2.1.8 Primers 
Table 12：Primers for QPCR  
Gene Company 
IL-1β Rn00580432_m1; Thermo Fisher Scientific  
IL-6 Rn01410330_m1; Thermo Fisher Scientific 
IL-10 Rn01483988_g1; Thermo Fisher Scientific 
C3 Rn00566466_m1; Thermo Fisher Scientific 
Cfb  Rn01526084_g1; Thermo Fisher Scientific 
Arg1 Rn00691090_m1; Thermo Fisher Scientific 
NGF Rn01533872_m1; Thermo Fisher Scientific 
BDNF Rn02531967_s1; Thermo Fisher Scientific 
GDNF Rn01402432_m1; Thermo Fisher Scientific 
CNTF Rn00755092_m1; Thermo Fisher Scientific 
FGF2 Rn00570809_m1; Thermo Fisher Scientific 
β actin Rn00667869_m1; Thermo Fisher Scientific 
NME2 Hs00897133_g1; Thermo Fisher Scientific 
CDH5 Hs00901465_m1; Thermo Fisher Scientific 
Notch 1 Hs01062014_m1; Thermo Fisher Scientific 
CTNNB1 Hs00355045_m1; Thermo Fisher Scientific 
GJA1 Hs00748445_s1; Thermo Fisher Scientific 
CAV1 Hs00971716_m1; Thermo Fisher Scientific 
ACTB Hs01060665_g1；Thermo Fisher Scientific 
 
2.1.9 Kits 
Table 13：Kits 
Kits Company 
Cell Tracker Green CMFDA Dye Thermo Fisher Scientific  
Subcellular Protein Fractionation 
Kit for cultured Cells 
Thermo Fisher Scientific 
Lumi-Light Western Blotting Roche 
Super Signal West Femto Thermo Fisher Scientific 
Centrifugal Filter Unit Microcon@ Centrifugal Filters Devices 
cOmpleteTM, EDTA-free Protease Roche 
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Inhibitor Cocktail  
GoScriptTM Reverse Transcriptase Promega 
 
2.1.10 Consumable materials 
Table 14：consumable materials 
Material Type Company 
Cell culture dishes 6 cm, 10 cm Sarstedt 
Cell culture flasks 175 cm2, 125 cm2 Sarstedt 
Cell culture multi-well plates 6-well, 12-well, 24-well Sarstedt 
Collecting tubes 50 mL, 15 mL Sarstedt 
Filter tips 1000 μL, 100 μL, 10 
μL 
Greiner Bio One 
MicroAmp® Fast Optical 
Reaction Plate 
96-well, 0.1 mL Applied Biosystems 
MicroAmp® Optical Adhesive 
Film 
 Applied Biosystems 
Microscope object slides 76×26 mm R. Langenbrinck 
Microscope round coverslips  Ø 12 mm Menzel 
Microscope square 
coverslips 
24×24 mm, 24×60 mm Carl Roth 
PCR tubes Multiply® µStrip Pro 8-
strip 
Sarstedt 
Pipette tips 1000 μL, 100 μL, 10 
μL 
Sarstedt 
Protran nitrocellulose transfer 
membrane 
2.5 μm  
 
Whatman 
Serological pipettes  5 mL, 10 mL, 25 mL Sarstedt 
Sterile syringes Omnifix® solo 1 mL B. Braun 
Whatman® filter paper  Whatman 
 
2.1.11 Apparatuses 
Table 15：Apparatuses 
Apparatuses Company 
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Laminar flow bench Heraeus/Thermo Fisher Scientific  
Incubator (37°C, 5% CO2) Memmert 
Water bath Thermo Fisher Scientific 
Centrifuge  Eppendorf/Thermo Fisher Scientific 
Gel imager Alpha imager 2000 
 
Shaker  Neolab 
Eletrophoresis chamber and apparatus Bio-Rad 
Mini-protein casting module Bio-Rad 
Heating block Eppendorf 
Voltmeter Biometra 
Vortex  Janke & Kunkel 
Pipette Sartorius 
Weighing machine Sartorius 
Pump  
Microprocessor PH meter WTW 
Spectrophotometer Thermolabsystems Multiscan EX 
NanoDrop Spectrophotometer PeQLab 
Stereomicroscope Zeiss/Olympus 
Fluorescence microscope Leica 
Confocal microscope Leica 
Scanning machine Zeiss Axio Scan Z1 
QPCR machine Applied Biosystems 
Millipore water machine Milli-QR 
Needle for intravitreal injection World Precision Instruments 
4°C fridge Bosch 
-20°C fridge Bosch 
-80°C fridge Thermo Fisher Scientific 
 
2.1.12 Software  
Table 16：Software 
Software Company 
Alpha imaging software Alphalmager@ Innotech 
Confocal microscope software Leica Application Suite X 
Zen blue Zeiss 
AnalysisPro Olympus 
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Image J  National Institutes of Health 
Bradford  Thermolabsystems Multiscan EX 
Blot image IrfanView 
Statistical software GraphPad Software Inc 
Reference software Endnote  
 
2.2   Methods 
2.2.1 Isolation of HUVECs 
Fresh human umbilical cords were put on clean pad and excess blood was 
removed. Fresh cuts were made on both ends of the cords. One end of the cord 
was sealed using a clamp and the other end was attached to a 3-way stopcock, 
allowing bidirectional flow of fluid through the vein, which was further washed 
using pre-warmed low glucose DMEM to remove the internal blood of the vein 
completely. 1×DMEM-Dispase II was used to digest the vein endothelial cells. 
The cord was incubated (37°C,5% CO2) for 30 min. The digested cells were 
collected by a 50-mL Falcon tube with 5-mL FCS to stop the enzymatic 
digestion. After centrifugation, the cells were collected and cultured in complete 
endothelial cell growth medium. 
2.2.2 HUVEC and pericyte culturing  
HUVECs were cultured on gelatin-coated flasks using endothelial cell growth 
medium supplemented with 10% FCS. Human pericytes were purchased from 
the company (ScienCell Research Laboratories) and were grown on gelatin-
coated flasks in the DMEM/F12 medium supplemented with 5% FCS, 1% 
penicillin-streptomycin, insulin (5 μg/mL), and bFGF (2 ng/mL).  
2.2.3 HUVEC-pericyte co-culture 
HUVECs were cultured in a 6-well plate coated with 1% gelatin. Cells were 
transfected with control siRNA or VE-cadherin siRNA, followed by changing of 
fresh complete endothelial cell medium 4 h after transfection. The next day, 
pericytes were added on the top of the HUVEC monolayer (pericytes: HUVECs 
= 1:3) and further co-cultured for 24 h in mixed medium containing 50% HUVEC 
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culturing medium and 50% pericyte culturing medium.  
 
For the quantification of attached pericytes, pericytes were incubated with anti-
NG2 antibody, and HUVECs were incubated with the anti-VE-cadherin antibody 
overnight at 4 °C. Then, after washing with PBS, the cells were incubated with 
the commensurate secondary antibodies at RT for 1 h. The slices were 
mounted with Roti-mount. Pericyte coverage was quantified from the average 
fluorescent intensity of five microscopic fields at 40× magnification using the 
ImageJ software.  
 
For the quantification of detached pericytes, before co-culture, pericytes were 
stained with Cell-TrackerTM Green dye (5μM) in a serum-free medium at 37 °C 
for 30 min; they were further incubated in a complete medium at 37 °C for 30 
min. The labeled pericytes were added on the HUVEC monolayer according to 
their seeding ratio. The detached pericytes were collected from the medium and 
were quantified using the cell counting chamber. The quantification was 
performed under a fluorescent microscope and the cell number was randomly 
measured in five microscopic fields at 10× magnification.  
2.2.4 RNA interference 
HUVECs were cultured in gelatin-coated 6-well plates using ECBM 
supplemented with 10% FCS. HUVECs at 70% confluence cultured in serum-
free OptiPRO medium (Life Technologies, Darmstadt, Germany) were 
transfected with NDPK B siRNA, VE-cadherin siRNA, and control siRNA using 
lipofectamine (Life Technologies, Darmstadt, Germany) according to the 
manufacturer’s protocol and incubated for 4 h. After transfection, the cells were 
re-cultured in ECBM supplemented with 10% FCS. Then, cells were starved in 
ECBM with 0.5% FCS overnight at 37°C, followed by stimulation with normal 
glycemic condition (5.5mM D-glucose) or hyperglycemic condition (30mM D-
glucose) for 24 h. The NDPK B and VE-cadherin knockdown were validated 
using western blot analysis. 
2.2.5 VE-cadherin internalization assay 
HUVECs were cultured in a cell chamber (Merck, Germany) coated with cross-
linked gelatin and glutaraldehyde. The cells were transfected with the NDPK B 
siRNA or control siRNA for 4 h at 70% confluence. The next day, cells were 
cultured in 2% FCS medium overnight. Then, the cells were incubated with VE-
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cadherin primary antibody (clone BV6, ALX-803-305, Enzo Life Sciences) at 
4°C for 1 h in MCDB 131 medium containing 1% BSA. After washing thrice with 
ice-cold MCDB 131 medium, the cells received 5 mM NG/30 mM HG for 30 min 
or VEGF (50 ng/mL) for 15 min at 37°C in the incubator. For assessment of VE-
cadherin internalization, cells were washed with ice-cold acid washing buffer 
(Hanks buffer, pH 2.7, containing 25 mM glycine and 1% BSA), and were fixed 
with 4% paraformaldehyde (PFA) for 15 min on ice. Then, the cells were 
incubated with 1% BSA containing 0.2% Triton X-100 in PBS overnight at 4°C. 
Subsequently, cells were incubated with rabbit anti-EEA1 (1:200, Thermo 
Fisher Scientific, USA) or rabbit anti-LAMP1 (1:200, Cell Signaling Technology, 
USA) overnight at 4°C. After washing thrice with PBS, the cells were incubated 
with the corresponding secondary antibodies, goat-anti-mouse Alexa Fluor 488 
(1:200, Life Technology, USA), and swine-anti-rabbit TRITC (1:30, Dako, 
Denmark) at RT for 1 h. The nuclei were stained with DRAQ5 (1:1000, Cell 
Signaling Technology, USA) for 5 min. The images were acquired using a 
fluorescent microscope or confocal microscope (Leica. Germany). 
2.2.6 Membrane protein extraction 
HUVECs were cultured in 6-well plates till they reached 70% confluence. After 
transfection and starvation, the cells were stimulated with or without HG (30 
mM) for 24 h. Subsequently, the cells were harvested using trypsin-EDTA and 
collected via centrifugation at 500 × g for 5 min. The subcellular protein 
fractionation kit was used for preparing the membrane extract.  
2.2.7 Isolation of human ASCs 
Human ASCs were isolated from lipoaspirate samples. ASCs were cultured in 
complete medium (DMEM, 10% fetal calf serum, penicillin, and streptomycin) 
and were characterized based on fibroblastoid morphology, adipose- and 
osteogenic differentiation potential, and immune phenotype.  
2.2.8 Isolation of rat BMSCs 
The femur and tibia isolated from healthy SD rats were dissected and used for 
isolating BMSCs. Tissues were immersed in PBS containing 2 mM EDTA, 100 
U/mL penicillin, and 100 μg/mL streptomycin (PS). A syringe was used for 
flushing the bone marrow cavity using PBS/2mM EDTA/PS. The liquid collected 
was centrifuged at 420 × g for 5 min. The cell pellet was then re-suspended in 
complete medium (DMEM, 10% rat serum, PS) and transferred to a 25 cm2 
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plastic flask and incubated overnight at 37 °C in a 5% CO2 incubator. The next 
day, the flasks were washed using PBS/EDTA, and the cells were cultured until 
they were subconfluent. 
2.2.9 Human ASC, rat BMSC, and RFPEC culturing  
Human ASCs were typically cultured in T75 or T125 flasks, and the medium 
(DMEM (low glucose) with 1% L-glutamine, 1% PS, and 10% FSC) was 
changed after every two days. Cells were split once till they reached 70−80% 
confluence. For passaging, the cells were first washed twice with PBS and then 
digested with trypsin at 37°C for 5 min. After all the cells had detached, 
complete medium was used to stop the digestion. Cells were plated in the new 
culturing flask at the density of 1 × 106 cells/cm2. 
 
Rat BMSCs were cultured in complete medium (DMEM (low glucose) with 1% 
L-glutamine, 1% PS, and 10% FSC). Upon reaching 70−80% confluence, the 
cells were digested using trypsin/EDTA. Afterward, the cells were seeded at the 
density of 3 ×105 cells in a T75 flask and cultured for 3 days. 
 
RFPECs were cultured in DMEM (1000mg/L glucose) supplemented with L-
glutamine, PS, and 10% FCS in a 5% CO2 incubator at 37°C.  
2.2.10 Concentration of human ASC supernatant  
Ten milliliters of human ASC culture supernatant were collected from the cell 
culturing flasks and concentrated using Microcon@ centrifugal filters devices. 
First, the tube was inserted in the Microcon@ centrifugal filters devices. Second, 
culture supernatant was pipetted into the device and was centrifuged at 14,000 
× g for 20 min. The liquid at the bottom of the tube was discarded, and the 
concentrated supernatant in the inserted tube was collected for the following 
concentration step. Finally, the injected culture supernatant was concentrated 
100 times from 100 mL. 
2.2.11 Cell labeling 
MSCs were labeled with Cell−TrackerTM Green CMFDA for monitoring their 
location in the eye post-injection. Initially, cells were washed with PBS and then 
collected after trypsin digestion. Subsequently, the cells were incubated in 1.5 
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mL Eppendorf tubes with a serum-free culture medium containing 5 µM 
Cell−TrackerTM Green CMFDA dye at 37 °C for 30 min. Afterward, the cells were 
re-incubated in a complete fresh medium at 37°C for 30 min. Finally, the cells 
were diluted in sterile PBS at the concentration of 10,000 cells/µL. 
2.2.12 Intravitreal injection  
Rats were anesthetized with isoflurane for the whole injection procedure. An 
anesthetic solution, Novesine@ 0.4% eye drop, was applied to both eyes. A 35-
gauge fine needle connected with a 10 µL syringe was used for injection into 
the vitreous cavity, under monitoring using an ophthalmic microscope. The left 
eyes were intravitreally injected with 2 µL of sterile PBS. The right eyes received 
injection of 20,000 cells in 2 µL.   
2.2.13 Retinal digestion and quantitative retinal morphometry 
The frozen eyes were immersed in 4% formalin solution at RT for 48 h. The 
eyes were washed thrice with PBS to remove the remaining fixation solution. 
Retina isolation was performed under the microscope. First, the eyeball was 
positioned forward by placing the forceps around the posterior part. After that, 
the cornea was removed using sharp scissors. After eliminating the lens and 
vitreous, the retina was carefully isolated using a micro-spatula.   
 
The retinas were initially sunk in deionized water at 37°C for 1 h and further 
incubated in Tris-HCl buffer (pH 7.0) containing 3% trypsin at 37°C for about 3 
h. The retinas were carefully moved onto a clean glass slide and washed with 
deionized water using a pump until no debris was left in the water, and the 
retinal vasculature network observed under the microscope. The retinas dried 
entirely at RT and subjected to period-acid-schiff (PAS) staining procedure for 
visualization of the retinal vasculature. The protocol of PAS staining was as 
follows: 
 
ddH2O 5 min 
1% Periodic acid 30 s 
ddH2O Short time 
Schiff’s reagent 30 s 
Running tap water 5 min 
ddH2O Short time 
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Mayer’s Hemalum 30 s 
Running tap water 7 min 
ddH2O Short time 
70% ethanol Short time 
80% ethanol Short time 
96% ethanol 5 min 
100% ethanol 5 min 
Roti®-histol ×3 5 min each 
Embed with Entellan® 
 
The number of pericytes and the acellular capillaries in 40× magnification 
images were used for quantification. Briefly, ten microscopic fields were 
selected randomly for each image. AnalysisPro (Olympus) was used for 
calculating cell and acellular capillary number. A special ocular containing a grid 
of 100 squares was required for the observation of acellular capillaries. The 
acellular capillaries present in the squares was recorded in ten randomly-
selected microscopic fields.  
2.2.14 Immunofluorescence staining 
The eyes were embedded in paraffin blocks, and retinal paraffin sections of 6-
µm thickness were made and deparaffinized after incubation at 60°C for 1 h. 
After cooling, the sections were further immersed in Roti-Histol, and 
subsequently in decreasing concentrations of ethanol (100% to 70%). After 
antigen retrieval using a citric buffer, the sections were immersed in a solution 
containing 2.5% BSA and 0.3% Triton X-100 for 2 h at RT. Next, the sections 
were immersed in primary antibody overnight at 4°C and were incubated with 
the corresponding secondary antibodies for 1.5 h at RT in the dark on the next 
day. DRAQ5 was used for nuclear staining.  
 
HUVECs were fixed using 4% PFA for 15 min on ice. After PBS washing, the 
cells were blocked and permeabilized overnight using 1% BSA + 0.2% Triton 
X-100 at 4°C. The cells were stained overnight with corresponding primary 
antibodies at 4°C. The next day, the cells were stained with the corresponding 
secondary antibodies at RT for 1 h in the dark. DRAQ5 was used for nuclear 
staining.  
 
For retinal whole-mount staining of VE-cadherin and lectin, the eyes were fixed 
41 
 
in 4% PFA on ice for 2 h. After three PBS washes, the retinas were dissected 
and incubated overnight in the blocking/permeabilization buffer (1% BSA+0.2% 
Triton X-100) at 4°C. Afterward, the retinas were incubated overnight with anti-
VE-cadherin antibody and anti-lectin conjugated with the TRITC antibody at 4°C. 
The retinas were incubated with a goat anti-mouse antibody at RT for 1 h. 
Finally, the retinas were mounted on the glass slides with Roti-mount. The 
images were acquired using a confocal laser scanning microscope. Retinal 
vascular VE-cadherin expression was quantified from the fluorescent intensity 
using the ImageJ software.  
2.2.15 Microglia quantification 
Microglia were quantified using immunofluorescence staining images. The eyes 
were fixed in 4% formalin for 24 h, and the retinas were isolated. After PBS 
washing, the retinas were blocked and permeabilized in a buffer containing 0.5% 
Triton X-100 and 1% BSA in PBS for 30 min. The retinas were then co-
incubated with the anti-Iba1 and anti-lectin antibody overnight at 4°C. After PBS 
washes, the retinas were then co-incubated with the corresponding secondary 
antibodies for 1 h at RT. Finally, the retinas were flat-mounted with Vectashield 
hard set mounting medium. Images were captured from five randomly-selected 
fields in the deep capillary layer using a confocal microscope. Iba1-positive cells 
were counted using ImageJ (v 1.50i) and calculated as a microglia/mm2 retinal 
area. 
2.2.16 Multifocal electroretinography    
Multifocal electroretinography (mfERG) was performed in this study. The rats 
were positioned in front of the RETImap machine, with a DTL electrode touching 
the cornea. Subcutaneous silver needle electrodes were inserted into the neck 
skin of the rats as the reference and ground electrodes. A contact lens with 
ninety dioptrics was mounted over viscous 2% methodical gel, which was then 
placed on the eyes of the mice. An array of seven equally-sized hexagons was 
selected. The simulation was conducted using 150 cd/m² and 1 cd/m² for the 
m-sequence with four dark frames in between the stimuli. An average of eight 
cycles was used for the final analyses. mfERG was recorded under photopic 
conditions, where both rod and cone photoreceptors were activated in rats. In 
terms of analysis, the response from the internal retina was quantified as a 
positive wave 1 (P1) regarding signal strength represented by P1 amplitude, 
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and signal velocity indicated by P1 implicit time. In this experiment, the P1 
amplitude, acting as an indicator of the inner retinal function and mainly 
generated by the Müller cells. was represented the b-wave in standard ERGs,  
2.2.17 Cryosectioning 
The eyes were fixed using 4% PFA for 4 h, followed by three washes with PBS. 
After the removal of the cornea and lens, the remaining tissue was placed in a 
20% sucrose solution for 30 min. Subsequently, the eye tissue was positioned 
vertically in a small cutting form with O.C.T compound and frozen at −20°C. 
Sectioning was performed with a cryostat. Cryosections were stained with DAPI 
for observing the nuclei and were finally mounted with the Roti-mount solution. 
2.2.18 Immunoblotting 
The proteins from retinas and cells, extracted using radioimmunoprecipitation 
assay (RIPA) buffer supplemented with protease inhibitor cocktail, were 
separated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and were further electrically transferred onto nitrocellulose 
membranes that were blocked with Roti-block at RT for 1 h. After washing with 
Tris-buffered saline with Tween-20 (TBST), the membranes were incubated 
with targeted primary antibodies in a Falcon tube on a shaker overnight at 4°C. 
Then, the blots were incubated with corresponding secondary antibodies at RT 
for 1 h. The blot was visualized using a chemiluminescent substrate and an 
imaging machine. Protein expression was analyzed using the ImageJ software.  
2.2.19 Dot blot 
One microliter of the aqueous humor from eyes dropped was onto a 
nitrocellulose membrane that was allowed to completely dry at RT. After 
blocking for 1 h, the blot was incubated overnight with goat anti-rat IL-1β 
primary antibody at 4°C. After washing thrice with TBST, the membrane was 
incubated with the corresponding secondary rabbit-anti-goat antibodies at RT 
for 1 h. Protein expression was analyzed using the ImageJ software. 
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2.2.20 Ex vivo experiments 
The eyes of PKD rats were intravitreally injected with 2 × 104 human ASCs 
labeled with Cell-TrackerTM Green and cultured in a 12-well plate in complete 
medium. Eyes were fixed in 4% PFA for 2 h on ice three days after the injection. 
After washing with PBS, the retinas were carefully dissected for whole-mount 
staining with an antibody against lectin conjugated with TRITC. The images 
were captured using an immunofluorescence microscope.  
2.2.21 Retinal RNA isolation  
The dissection instruments were sequentially disinfected with 70% ethanol, 
distilled water, and RNaseZAP. Rat retinas were isolated from eyes and were 
transferred to a 1.5 mL Eppendorf tube filled with 300 µL Trizol. Retinas were 
homogenized through a syringe connected sequentially with 22G, 25G, and 
27G needles in this order. Subsequently, 700 µL Trizol was added to the tubes 
with the retina solution and mixed well manually. The tube was placed at RT for 
5 min, followed by the addition of 200 µL chloroform into 1 mL Trizol solution. 
Subsequently, the tube was intensely shaken manually for 15−20 s and was 
placed at RT for 2−3 min. After centrifuging at 12,000 × g for 15 min at 4°C, 500 
µL of the top aqueous phase was aspirated out and transferred into another 
new tube, to which 500 µL isopropanol was added to precipitate RNA via 
centrifugation at 12,000 × g for 30 min at 4°C. The RNA pellet was washed 
using 75% ethanol. Finally, the RNA was completely air-dried and dissolved in 
20 µL diethyl pyrocarbonate (DEPC)-treated water. 
2.2.22 Real-time polymerase chain reaction (PCR) 
The RNA concentration was measured with a Nanodrop machine. RNA was 
reverse-transcribed to cDNA using the GoScriptTM reverse transcription kit. The 
program for cDNA synthesis was as follows: annealing at 25°C (5 min)—
extension at 42°C (60 min)—inactivation of reverse transcriptase at 70°C (15 
min). The cDNA was diluted 1:5 in RNase-free water for real-time PCR. TaqMan 
Fast advanced master mix was utilized for real-time PCR. All primers and MGB 
probes labeled with FAM dye for amplification were purchased from Applied 
Biosystems-Thermo Fisher Scientific. Gene expression was analyzed using the 
-ΔΔCT method. The expression of each target gene was standardized to that 
of the housekeeping gene encoding β actin.  
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2.2.23 Retinal perfusion  
Mice were anesthetized using isoflurane inhalation. Cervical dislocation was 
performed after short anesthesia. Mice were immobilized firmly in a stereotactic 
device. Medical scissors were used to carefully open the chest cavity and a 
perfusion syringe was inserted in the left ventricle. The right atrium was pierced 
with a needle for inducing blood outflow. For removal of retinal vessel blood, 10 
mL of saline was slowly perfused in the left ventricle of mice for 5 min until the 
mice's eyes turned white. Immediately after the perfusion, the eyes were 
enucleated and stored in liquid nitrogen. 
2.2.24 Statistical analysis 
All the data were presented as mean ± SD. Student t-test or two-way analysis 
of variance (ANOVA) was performed using GraphPad Prism 5 (GraphPad 
Software, La Jolla, CA, USA). P values < 0.05 were considered significant. 
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3 Results  
3.1 The role of VE-cadherin in retinal vasoregression 
3.1.1 VE-cadherin expression is reduced in NDPK B deficient retinas 
before pericyte loss 
To investigate the role of VE-cadherin in the progression of retinal vascular 
degeneration, we detected the expression of retinal VE-cadherin in NDPK B-/- 
mice. As shown in Fig. 14, western blot analysis confirmed the deficiency of 
NDPK B in knockout retinas. Retinal VE-cadherin expression was evaluated in 
NDPK B-/- mice at different ages (from 1 to 5 months). Retinal VE-cadherin 
expression in 1- and 3-month old NDPK B-/- mice did not vary significantly from 
that of their age-matched control mice. However, 4-month-old NDPK B-/- mice 
started to show a substantial decrease in retinal VE-cadherin expression, which 
was further reduced in 5-month-old NDPK B-/- mice (Fig. 15A and B). We had 
previously detected pericyte loss in 8-month-old NDPK B-deficient retinas (Qiu 
et al., 2016). To identify the initial time point of pericyte loss in NDPK B-/- retinas, 
we assessed the pericyte coverage of retinal capillary in WT and NDPK B-/- 
mice at 4 and 5 months. Retinal pericyte coverage between NDPK B-/- and WT 
retinas did not vary significantly at 4 months. However, as shown in Fig. 16A 
and B, the number of pericytes in 5-month-old NDPK B-deficient retinas was 
significantly lower than that in WT retinas (P < 0.05). These data suggest that 
the reduced expression of retinal VE-cadherin occurs before pericyte loss, 
which is the first sign of hyperglycemia-independent retinal vasoregression in 
NDPK B-/- mice. 
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Figure 14: NDPK B depletion in retinas of NDPK B-/- mice. NDPK B was not 
expressed in the retinas of NDPK B-/- mice as shown using western blot analysis 
 
 
 
Figure 15: VE-cadherin expression is reduced in NDPK B-deficient retinas. (A) 
VE-cadherin expression in the retinas of WT and NDPK B-/- mice of different ages (1, 
3, 4, and 5 months) determined using western blot analysis. Reduction in the 
expression of VE-cadherin in the retinas of NDPK B-/- mice was initiated at 4 months 
and progressed at 5 months. (B) Quantification of western blot data. VEC: VE-cadherin; 
NDPK B-/-: NDPK B knockout. * P < 0.05. ** P < 0.01. n = 3. 
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Figure 16: Retinal pericyte loss is observed in 5-month-old NDPK B-/- mice. (A) 
Retinal digestion was performed in 4- and 5-month-old WT and NDPK B-/- mice. Retinal 
digestion preparations were stained with PAS stain to show retinal endothelial cells, 
pericytes, and capillary. (B) Quantification of retinal pericyte coverage in 4- and 5-
month-old WT and NDPK B-/- mice. The number of retinal pericytes decreased 
significantly in 5-month-old NDPK B-/- mice compared to in age-matched control mice. 
** P < 0.01; n = 6-8. 
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3.1.2 VE-cadherin expression is reduced in the retinas of PKD rats before 
pericyte loss 
We have previously reported that PKD rats develop retinal vasoregression at 2 
months, which is driven by retinal photoreceptor degeneration. To determine 
whether the reduction in the expression of retinal VE-cadherin precedes 
pericyte loss in PKD rats, we analyzed the expression of retinal VE-cadherin in 
1- and 3-month-old rats. Results demonstrated that the expression of retinal 
VE-cadherin was significantly lower in both 1- and 3-month-old PKD rats than 
in the age-matched control rats (Fig. 17A and B). This indicates that the 
reduction in the expression of VE-cadherin in retinas occurs earlier than 
pericytes loss in the retinopathy models associated with neurovascular unit 
damage and without hyperglycemia. 
 
 
Figure 17: Reduced expression of VE-cadherin in the retinas of PKD rats. (A) The 
assessment of VE-cadherin expression in retinas of 1- and 3-month-old SD and PKD 
rats using western blot analysis. (B) Quantification of retinal VE-cadherin expression 
in SD and PKD rats. Retinal VE-cadherin expression was markedly reduced in both 1- 
and 3-month-old PKD rats. VEC: VE-cadherin. * P < 0.05. n = 3.  
3.1.3 VE-cadherin expression is reduced in the retinas of Ins2Akita mice 
before pericyte loss 
Ins2Akita mice harbors mutation in the insulin gene, which causes hyperglycemia 
in as early as 4 weeks; hence they are considered proper models of early 
retinopathy in diabetes and developed pericyte loss in retinas at 8 weeks of age 
(Barber et al., 2005). To investigate whether reduced expression of retinal VE-
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cadherin arises before pericyte loss in Ins2Akita mice, we evaluated retinal VE-
cadherin expression in 6-week-old Ins2Akita mice. As expected, in 6-week-old 
Ins2Akita mouse retinas, we detected a significant reduction in VE-cadherin 
expression compared to that in the age-matched control mouse retinas (Fig. 
18A and B). These results indicate that hyperglycemia-induced retinal 
vasoregression is associated with the reduction of retinal VE-cadherin 
expression. 
 
Figure 18: VE-cadherin expression is reduced in the retinas of Ins2Akita mice. (A) VE-
cadherin expression was detected in the retinas of 6-week-old Ins2Akita and control 
mice by Western blot. (B) Ins2Akita mice displayed significantly reduced VE-cadherin 
expression in retinas. VEC: VE-cadherin. * p<0.05. n=3. 
3.1.4 VE-cadherin expression is reduced in deep retinal capillaries of 
NDPK B-/- mice 
Considering the general link between VE-cadherin and pericyte loss and slow 
development of pericyte loss within three models, we next mainly focused on 
NDPK B-/- mice. The retinal vascular network includes a superficial layer, an 
intermediate layer, and a deep capillary layer (Spaide et al., 2015; Stone et al., 
1995). To determine which retinal vascular layer is mainly impaired, the 
morphology of retinal vasculature was assessed using retinal whole-mount 
staining. Immunofluorescent staining showed no significant change in VE-
cadherin expression of retinal arteries and veins; however, a significant 
decrease in VE-cadherin expression was observed in deep retinal capillaries 
(Fig. 19). These observations indicate that NDPK B deficiency-induced VE-
cadherin reduction mainly involves retinal capillaries, which initially develop 
pericyte loss.   
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Figure 19: VE-cadherin level is reduced in deep retinal capillaries of NDPK B-/-
mice. (A, B, and C) Retinal vasculatures were visualized with lectin (red) and VE-
cadherin (green). The images were captured using a confocal microscope. (D) 
Quantification of VE-cadherin fluorescence intensity in the retinal artery, vein, and 
capillary was measured using the ImageJ software. ** P < 0.01; n = 3. 
3.1.5 Reduced expression of VE-cadherin in endothelial cells is 
associated with pericyte loss 
As the reduced expression of retinal VE-cadherin preceded pericyte loss in 
three retinopathy models, we next investigated whether VE-cadherin deficiency 
in endothelial cells induces pericyte loss in vitro. We used siRNA targeting VE-
cadherin mRNA to silence VE-cadherin expression in HUVECs. As shown in 
Fig. 20A and B, the knockdown efficiency at the protein level was significant at 
24 h and remained so until 96 h, compared to that observed using scrambled 
siRNA-transfected cells. We further assessed whether VE-cadherin deficiency 
in endothelial cells destabilizes pericytes in a co-culture system. The 
quantification of pericytes in medium revealed no significant difference between 
control and VE-cadherin knock-down groups after co-culture until 10 h. 
However, we detected a significant elevation in the number of medium pericytes 
in the VE-cadherin knock-down group post-co-culture for 24 h (Fig. 21C). 
Consistently, the data from immunofluorescent staining demonstrated that the 
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coverage of pericyte to endothelial cells in the VE-cadherin knock-down group 
was significantly lower than that in the control group (Fig. 21D and E). These 
data indicate that VE-cadherin stabilizes the contact between endothelial cells 
and pericytes. 
 
 
Figure 20: Reduced expression of VE-cadherin in endothelial cells is associated 
with pericyte loss. (A) HUVECs were transfected with either scrambled siRNA or VE-
cadherin siRNA, and the knockdown efficiency of VE-cadherin was detected using 
western blotting until 96 h. (B) A significant reduction in VE-cadherin expression was 
detected in HUVECs within 96 h. (C) After knockdown of VE-cadherin in HUVECs for 
24 h, human pericytes labeled with Cell-TrackerTM Green were seeded on the top of 
endothelial cell monolayer in 1:3 ratio (pericytes: HUVECs). The quantification of 
medium pericytes was measured using a fluorescent microscope by counting cell 
numbers in five random 10x fields. (D) After co-culture of pericytes and endothelial 
cells for 24 h, the cells were stained with NG2 (green), VE-cadherin (red), and DRAQ5 
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(blue). (E) Pericyte coverage was quantified using the ImageJ software. * P < 0.05, ** 
P < 0.01, n = 3.  
3.1.6 NDPK B-/- mice display increased permeability of retinal vasculature 
To investigate whether NDPK B deficiency induces hyperpermeability of retinal 
vessels, we evaluated the endogenous albumin level of the retina after saline 
perfusion in WT and NDPK B-/- mice (5-month-old). Results of western blotting 
demonstrated that the endogenous albumin level in the retina of NDPK B-/- mice 
was significantly higher than that in control mice (Fig. 21A and B). This 
indicates that NDPK B deficiency causes hyperpermeability of retinal vessels.    
 
 
 
Figure 21: Retinal vascular hyperpermeability in NDPK B-/- mice. (A) Retinal blood 
was removed via saline perfusion. Retinal albumin levels were used to evaluate retinal 
vascular leakage via western blotting. (B) NDPK B-/- mice displayed significant increase 
in retinal vascular permeability. * P < 0.05; n = 5. 
3.1.7 NDPK B loss or HG reduces plasma membrane VE-cadherin levels 
in endothelial cells 
In endothelial cells, NDPK B contributes to barrier integrity. The brains of NDPK 
B-/- mice showed increased vascular permeability (Gross et al., 2017). Early 
studies have reported that HG downregulates VE-cadherin (Cao et al., 2014; 
Rangasamy et al., 2011). To better analyze how NDPK B deficiency or HG 
induces VE-cadherin degradation, we treated endothelial cells with scrambled 
siRNA or siNDPK B and then stimulated them with HG for 24 h. The results of 
western blotting demonstrated that membranous VE-cadherin expression in 
NDPK B-depleted cells and HG-treated cells was significantly lower than that 
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in control cells (Fig. 22A and B). Immunofluorescent images further showed 
that in endothelial cells treated with scrambled siRNA, VE-cadherin was 
distributed in zipper-like pattern, whereas NDPK B-depleted cells and HG-
treated cells displayed linear distribution of membranous VE-cadherin (Fig. 
22C). Quantification demonstrated a significant reduction in membranous VE-
cadherin expression in either NDPK B deficient or HG-treated endothelial cells 
(Fig. 22D). However, we did not examine further VE-cadherin reduction in 
NDPK B-depleted endothelial cells treated with HG. 
 
To exclude HG-induced osmotic effects on endothelial VE-cadherin expression, 
endothelial cells were exposed to L-glucose as an osmotic control. The results 
showed lack of any significant difference in VE-cadherin expression between 
L-glucose-treated cells and non-treated cells. On the contrary, VE-cadherin 
expression in D-glucose-treated cells was significantly lower than that in the 
osmotic control (Fig. 23).  
 
We further investigated whether NDPK B deficiency or HG treatment alters the 
expression of junctional molecules in endothelial cells using qPCR. The results 
demonstrated that the expression of VE-cadherin and other junctional 
molecules at the mRNA level are unaltered (Fig. 24). 
 
p120-catenin stabilizes VE-cadherin and regulates VE-cadherin turnover (Oas 
et al., 2013). Therefore, we next investigated the expression of β-catenin and 
p120-catenin in NDPK B-deficient cells and HG-stimulated cells. Results 
demonstrated that NDPK B deficiency or HG stimulation in HUVECs did not 
affect the expression of β-catenin and p120-catenin (Fig. 25). Thus, these data 
suggest that NDPK B deficiency induces similar effects as HG on endothelial 
VE-cadherin, leading to linear arrangement and reduced expression of 
membranous VE-cadherin. 
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Figure 22: NDPK B loss or HG reduces levels of membranous VE-cadherin. 
HUVECs were transfected with either NDPK B siRNA or scrambled siRNA and 
incubated for 4 h. Afterward, the cells were starved in 0.5% FCS culture medium for 
24 h. Cells were stimulated with either normal glucose (5.5 mM) or HG (30 mM) for 24 
h. (A) Membranous VE-cadherin was extracted. Both NDPK B loss and HG reduced 
membrane VE-cadherin expression. The NDPK B-depleted HUVECs treated with HG 
did not exhibit any further decrease in membranous VE-cadherin expression. (B) 
Membrane VE-cadherin was quantified in these four different groups. (C) HUVECs 
were stained with VE-cadherin (green) to show cellular VE-cadherin distribution. The 
linear change in VE-cadherin distribution was observed in treated groups (NDPKB 
knockdown, HG treatment, and combination). (D) Membrane VE-cadherin expression 
was quantified from the fluorescent intensity using the ImageJ software. NG: normal 
glucose; HG: high glucose; sicon: control siRNA; siNDPK B: NDPK B siRNA.  * P < 
0.05; n = 3. 
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Figure 23: VE-cadherin localization and expression in NG-, L-G- and D-G-treated 
endothelial cells. (A) VE-cadherin distribution was detected using immunofluorescent 
staining. Compared to the control, L-glucose-treated cells did not show any differences 
in VE-cadherin localization and distribution, whereas D-glucose-treated cells displayed 
decreased expression of VE-cadherin at cell-cell contacts. (B) Evaluation and (C) 
quantification of VE-cadherin expression was performed using western blotting and 
statistical analysis, respectively. D-glucose significantly reduced the expression of VE-
cadherin, whereas L-glucose did not affect the expression of VE-cadherin in the 
endothelial cells. NG: normal glucose; L-G: L-glucose; D-G: D-glucose. * P < 0.05; n = 
3. 
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Figure 24: NDPK B depletion or HG does not affect the mRNA expression of 
junctional molecules in endothelial cells. Quantification of the transcription of 
adhesion junction molecules using qPCR. NG: normal glucose; HG: high glucose; 
sicon: control siRNA; siNDPK B: NDPKB siRNA. n = 3.  
 
 
 
 
Figure 25: NDPK B deficiency or HG dose not affect the expression of β catenin 
and p120-catenin in endothelial cells. HUVECs were transfected with scrambled 
siRNA or NDPK B siRNA for 4 h and were starved in culture medium with 0.5% FCS 
for another 24 h. Subsequently, cells were treated with or without HG (30 mM) for 24 
h. The cell lysate was used for the evaluation of target protein using western blotting. 
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(A) NDPK B deficiency or HG did not change the expression of β catenin and p120-
catenin. (B and C) Quantification of western blotting data from graph A. NG: normal 
glucose; HG: high glucose. sicon: control siRNA; siNDPK B: NDPK B siRNA. n = 3. 
3.1.8 NDPK B loss or HG promotes VE-cadherin internalization and VE-
cadherin Tyr 685 phosphorylation in endothelial cells 
Increased VE-cadherin internalization induced gap formation between 
endothelial cells (Cao and Schnittler, 2019). Therefore, we further investigated 
whether either NDPK B deficiency or HG treatment leads to VE-cadherin 
internalization in endothelial cells. Immunofluorescent images demonstrated 
that VE-cadherin is predominantly located at cell-cell contact sites without acid 
washing. After acid washing, membranous VE-cadherin disappeared, and 
internalized VE-cadherin remained in the cytosol of control cells. VE-cadherin 
internalization was significantly lower after NDPK B knockdown and HG 
stimulation for 30 min than in the control cells. VEGF, as a positive control, 
remarkably induced VE-cadherin internalization after stimulation for 15 min (Fig. 
26). We did not observe further increased VE-cadherin internalization in NDPK 
B-depleted endothelial cells treated with HG.  
 
An early study showed that increased Tyr 685 phosphorylation of VE-cadherin 
is associated with its internalization (Wu et al., 2016). Therefore, we further 
analyzed whether either NDPK B deficiency or HG treatment in endothelial cells 
may increase Tyr 685 phosphorylation of VE-cadherin. Immunoblotting showed 
that VE-cadherin phosphorylation at the Tyr 685 site is significantly enhanced 
under either NDPK B knockdown or HG condition (Fig. 27). The NDPK B-
depleted endothelial cells treated with HG did not display further increase in Tyr 
685 phosphorylation of VE-cadherin compared to that in the control group. 
Hence, these results indicate that increased VE-cadherin internalization caused 
by NDPK B loss or HG stimulation is mediated via increased Tyr 685 
phosphorylation of VE-cadherin.  
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Figure 26：NDPK B deficiency or HG promotes VE-cadherin internalization in 
endothelial cells. After transfection with either scrambled siRNA or NDPK B siRNA 
for 4 h in HUVECs, cells were further starved in 0.5% FCS culture medium for another 
24 h. Cells were stained with an antibody against VE-cadherin extracellular domain 
(BV6) on ice for 1 h and were then stimulated with either normal glucose (5 mM) or HG 
(30 mM) for 30 min. (A) Both NDPK B deficiency and HG treatment promoted VE-
cadherin internalization, similar to the effects induced by VEGF treatment as a positive 
control. Acid washing was used to remove the remaining membrane-bound VE-
cadherin. All the membrane-bound VE-cadherin persisted in the absence of acid 
washing. (B) Quantification of internalized VE-cadherin from the fluorescent intensity 
of internalized VE-cadherin using ImageJ. (C) NDPK B knockdown efficiency was 
detected using western blotting. NG: normal glucose; HG: high glucose; sicon: control 
siRNA; siNDPK B: NDPK B siRNA. *** P < 0.001; n = 3. 
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Figure 27: NDPK B deficiency or HG increases VE-cadherin Tyr 685 
phosphorylation in endothelial cells. HUVECs were transfected with scrambled 
siRNA or NDPK B siRNA for 4 h. After starvation in culture medium with 0.5% FCS for 
24 h, the cells were treated with or without HG (30 mM) for 30 min. (A) Increased VE-
cadherin Tyr 685 phosphorylation was observed under NDPK B deficiency and in HG-
treated groups. (B) The graph shows the quantification of western blotting data. (C) 
VEGF stimulation for 15 min increased VE-cadherin Tyr 685 phosphorylation 
compared to that in the non-VEGF treatment group. (D) Quantification of western 
blotting data from graph C. NG: normal glucose; HG: high glucose; sicon: control 
siRNA; siNDPK B: NDPK B siRNA. * P < 0.05, ** P < 0.01; n = 3. 
3.1.9 NDPK B loss or HG induces lysosome-mediated VE-cadherin 
degradation in endothelial cells 
Internalized VE-cadherin was captured by lysosomes for degradation (Chichger 
et al., 2016). Therefore, we investigated whether NDPK B deficiency or HG 
treatment promoted lysosome-mediated degradation. Endothelial cells were 
stained with extracellular VE-cadherin, EEA1 (a marker for early endosome), 
and LAMP1 (a marker for lysosome). We analyzed the colocalization of 
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internalized VE-cadherin with EEA1 and LAMP1 under the NDPK B deficiency 
and HG conditions. Immunofluorescent images demonstrated that internalized 
VE-cadherin triggered by the loss of NDPK B or HG was first captured by early 
endosomes in the cytosol, and they further were transported to lysosome with 
continuous loss of NDPK B or HG treatment (Fig. 28). These results suggest 
that the loss of NDPK B or HG treatment in endothelial cells induces lysosome-
mediated degradation. 
 
Figure 28: NDPK B deficiency or HG promotes lysosomal-mediated VE-cadherin 
degradation in endothelial cells. HUVECs were transfected with either scrambled 
siRNA or NDPK B siRNA for 4 h and were starved in 0.5% FCS culture medium for 24 
h. Then, the cells were incubated with an antibody against the extracellular domain of 
VE-cadherin on ice for 1 h. For evaluation of colocalization of internalized VE-cadherin 
and EEA1, cells received either NG or HG treatment for 30 min. For evaluation of 
colocalization of internalized VE-cadherin and LAMP1, cells received either NG or HG 
treatment for 24 h. (A) Either NDPK B deficiency for 48 h or HG treatment for 30 min 
promoted colocalization of internalized VE-cadherin (green) combined with endosome 
marker (EEA1, red). (B) Either NDPK B deficiency for 72 h or HG treatment for 24 h 
promoted colocalization of internalized VE-cadherin (green) combined with lysosome 
marker (LAMP1, red). (C and D) Quantification of the colocalization of internalized VE-
cadherin, EEA1, and LAMP1 using Pearson correlation coefficient analysis. NG: 
normal glucose; HG: high glucose; sicon: control siRNA; siNDPK B: NDPK B siRNA. * 
P < 0.05, ** P < 0.01; n = 3. 
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3.1.10 NDPK B deficiency or HG induces phosphorylation of VE-cadherin 
at Tyr 685 via Src kinase activation 
Src tyrosine kinase plays a key role in many cellular events, including cell 
proliferation, adhesion, migration, and differentiation (Krymskaya et al., 2005). 
Early reports revealed that VE-cadherin phosphorylation relies on Src kinase 
activation (Alcaide et al., 2012). To address these issues, we investigated 
whether NDPK B loss or HG induces increase in VE-cadherin phosphorylation 
via Src kinase. Compared to that in the control, we detected a significant 
increase in endothelial VE-cadherin tyrosine 685 phosphorylation and Src 
tyrosine 416 phosphorylation under either NDPK B knockdown or HG treatment 
condition. Furthermore, these increased effects on VE-cadherin and Src 
phosphorylation induced by NDPK B loss or HG stress in endothelial cells were 
partially inhibited by stimulation with pp2 (Fig. 29). These results suggest that 
increased VE-cadherin phosphorylation caused by NDPK B deficiency or HG 
treatment is mediated by the Src kinase. 
 
 
Figure 29: NDPK B deficiency or HG induces phosphorylation of VE-cadherin at 
Tyr 685 via Src kinase activation. HUVECs were transfected with either non-
targeting siRNA or NDPK B siRNA for 4 h and were then cultured in a 0.5% FCS culture 
62 
 
for 24 h. Afterward, cells were pre-treated with either DMSO or pp2 inhibitor (10 µM) 
for 1 h. Then, the cells were treated with either NG or HG for a further 30 min. (A) 
Representative immunoblots of VE-cadherin Tyr 685 phosphorylation, VE-cadherin, 
Src Tyr 416 phosphorylation, Src, NDPK B, and tubulin. (B and C) Quantification of p-
VEC Y685 to total VEC and p-Src Y416 to total Src. NDPK B deficiency or HG 
treatment increased the VE-cadherin Tyr 685 phosphorylation and Src Tyr 416 
phosphorylation. These effects were reversed by treatment with Src inhibitor (PP2). 
NG: normal glucose; HG: high glucose; sicon: control siRNA; siNDPK B: NDPK B 
siRNA. * P < 0.05, ** P < 0.01, *** P < 0.001; n = 4.   
3.2 Intravitreal injection of MSCs as a therapeutic intervention 
in vasoregressive retina 
 
3.2.1 Characterization of MSCs 
 
Prior to intravitreal injection of MSCs derived from rat bone marrow, we 
analyzed the cell surface markers of MSCs using FACs. Results indicated that 
MSCs were positive for CD44 (99.8%) and CD90 (99.7%), but were negative 
for CD45 (2%), which is considered as the marker for leukocytes and 
hematopoietic stem cells (Fig. 30). 
Figure 30: Characterization of rat BMSCs. BMSCs highly express CD90 (p7) and 
CD44 (p6) as typical MSC markers, but not CD45 (p5), a hematopoietic stem cell 
marker. Permission obtained from copyright © 2019 John Wiley and Sons (Huang et 
al., 2019b). 
 
3.2.2 Intravitreally injected MSCs are unable to migrate into the retina of 
the rat eye 
 
To determine whether MSCs may migrate into the retina, we initially injected 
human ASCs labeled with fluorescent dye using Cell-TrackerTM Green into the 
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vitreous cavity of PKD rat ex vivo. Three days after injection, we observed that 
most labeled cells remained in the vitreous cavity (Fig. 31A). We further 
injected labeled rat BMSCs into the rat vitreous cavity in vivo. Seven days after 
the injection, retinal whole-mount staining showed that only a few labeled cells 
were dispersed on the superficial layer of retinal capillary and that these labeled 
cells were unable to reach the deep layer of the retinal capillary (Fig. 31B). To 
further verify inability of MSCs to migrate into the retina, we analyzed the 
location of labeled cells in the retina after intravitreal injection using retinal 
cryosections. The images showed that labeled cells were limited to the retinal 
ganglion cell layer (GCL) and were blocked by the retinal inner limiting 
membrane (ILM). No labeled cells were seen in the inner retina (Fig. 31C). 
These data suggest that intravitreally injected MSCs are incapable of migrating 
into the retina. 
 
Figure 31: Intravitreally administrated MSCs can not migrate into the retina ex 
64 
 
vivo and in vivo. The eyes of PKD rats were intravitreally injected with either human 
ASCs or rat BMSCs labeled with Cell-tracker Green (2 × 104 in 2 µL PBS) ex vivo and 
in vivo. A) Three days after injection, most of the labeled human ASCs remained in the 
vitreous cavity ex vivo. The white arrow indicates the lens. The red arrow indicates 
human ASCs. White arrowhead indicates the vitreous cavity. The labeled cells (green) 
indicate human ASCs. B) Seven days after injection in vivo, visualization of retinal 
whole-mount staining using confocal microscopy demonstrated that a few labeled 
BMSCs (green) were confined on the superficial retinal layer in the whole mount 
staining and did not migrate into the deep retinal capillary layer. C) Cryosection staining 
demonstrated that labeled BMSCs (red arrow) cannot migrate into inner retinas 7 days 
after intravitreal injection in vivo. Lectin: retinal vessel staining; DAPI: nuclear staining. 
Scale = 50 µm. Permission obtained from copyright © 2019 John Wiley and Sons 
(Huang et al., 2019b). 
 
3.2.3 Intravitreally injected BMSCs induce cataract and retinal 
vasoregression in SD rats 
 
To evaluate the effect of intravitreally injected MSCs on rat retina, we 
administrated BMSCs isolated from healthy SD rats (8-week-old) into the 
vitreous space of 1-month-old SD rats. The eyes were evaluated after a four-
week injection. As shown in Fig. 32A, the lenses of SD rats injected with 
BMSCs, either isolated immediately after enucleation of the eyes or during 
retinal digestion, demonstrated opacity (100%) comparable to that of the control. 
We further evaluated the retinal vascular outcomes upon intravitreally 
administering BMSCs using retinal digest preparations. Surprisingly, intravitreal 
injection of BMSCs led to a 21% reduction in pericyte coverage in the retinal 
capillaries (1661 ± 52 in the BMSC-injected right eye vs. 2096 ± 29 cells per 
mm2 of the capillary area in control left eye, P < 0.01, Fig. 32B and C). 
Furthermore, the formation of acellular capillary was significantly increased 
after BMSC injection in retinas of SD rats by 205% (63.6 ± 2.9 in the BMSC-
injected eye vs. 18.8 ± 1.59 per retinal area in the control eyes, P < 0.001, Fig. 
32B and D). These results suggest that intravitreal injection of BMSCs induces 
lens opacity and retinal vasoregression in healthy rat eyes. 
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Figure 32: Intravitreally injected BMSCs lead to cataract formation and retinal 
vasoregression in SD rats. The eyes of SD rats were injected with PBS (left eye; 2 
µL) or BMSCs (right eye; 2×104 in 2 µL PBS) at P30. A) Four weeks post-injection, the 
lenses were isolated from the eyes and were immediately placed on the grid for 
evaluation of lens transparency, as shown in the left image. The right image displays 
the lens isolated from eyes after 4% formalin fixation for 48 h during retinal digestion. 
BMSC injection-induced cataract/lens opacity compared to PBS injection. B, C, D) 
Retinal digestion stained with PAS showed that BMSC injection significantly decreased 
the number of pericytes (C) and increased acellular capillary formation (D) compared 
to that in the controls. Red arrows indicate acellular capillaries. ** P < 0.01, *** P < 
0.001. Scale bar = 100 µm. n = 5. Permission obtained from copyright © 2019 John 
Wiley and Sons (Huang et al., 2019b). 
 
3.2.4 Intravitreally injected BMSCs aggravate retinal vasoregression in 
PKD rats 
 
We further assessed the effects of intravitreally injected BMSCs on PKD rat 
retinas with obvious vasoregression. Our early data already demonstrated that 
retinal vasoregression progressed in PKD rats at 2 months, mimicking the 
retinal vascular pathology that constantly occurs in DR. As mentioned before, 
we intravitreally administrated BMSCs into the vitreous space of 1-month-old 
PKD rats and evaluated the effects of retinal vasculature after a 4-week 
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injection. Interestingly, we observed that BMSC-injected PKD eyes have 
opaque lens (3 out of 5) (Fig. 33A). The data from retinal digestion showed 23% 
decrease in pericyte coverage (BMSC-injected vs. control: 1321 ± 93 and 1742 
± 47 per mm2 of capillary area; P < 0.05, Fig. 33B and C), and 72% increase 
in acellular capillaries (BMSCs-injected vs. control: 122 ±11 vs. 71 ±3.7 per 
retinal area; P < 0.01, Fig. 33B and D). We further intravitreally injected non-
starved BMSCs into PKD rats, showing that BMSCs induced 21% reduction in 
pericyte coverage (BMSCs-injected vs. control: 1608 ± 87 and 2040 ± 92 per 
mm2 of capillary area; P < 0.001, Fig. 34A and B) and 56% increase in acellular 
capillaries (BMSC-injected vs. control: 103 ±10 vs. 65 ±7 per retinal area; P < 
0.001, Fig. 34A and C). Therefore, these results suggest that intravitreal 
administration of BMSCs aggravates retinal vasoregression in PKD rats. 
 
 
Figure 33: Intravitreally injected BMSCs induce cataract formation and aggravate 
retinal vasoregression in PKD rats. PBS (left eye; 2 µL) or BMSCs (right eye; 2 × 
104 in 2 µL PBS) were injected into the vitreous cavity of PKD rats at P30. A) The lens 
transparency was analyzed 4 weeks post-injection using the grid, as shown in the left 
image. The right image displays the lens isolated from the eyes after 4% formalin 
fixation for 48 h during retinal digestion. Lens opacity was observed peripherally in the 
BMSC-injected eyes. B-D) PAS staining (B) shows that pericyte loss (C) and formation 
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of acellular capillaries (D) was further increased after BMSC injection compared to that 
observed after PBS injection. A red arrow indicates acellular capillaries. ** P < 0.01. 
Scale bar = 100 µm. n = 5. Permission obtained from copyright © 2019 John Wiley and 
Sons (Huang et al., 2019b) 
 
 
 
Figure 34: Intravitreal injection of non-starved BMSCs aggravates retinal 
vasoregression in PKD rats. PBS (left eye; 2 µL) or BMSCs (right eye; 2 × 104 in 2 
µL PBS) were injected into the vitreous cavity of PKD rats at P30. A) Retinal digestion 
stained with PAS showed that BMSC injection significantly decreased the number of 
pericytes (B) and increased acellular capillary formation (C) compared that in the 
controls. Red arrows indicate acellular capillaries. *** P < 0.001. Scale bar = 50 µm. n 
= 5 
 
3.2.5 Intravitreally injected human ASCs lead to retinal vasoregression in 
SD rats and aggravate retinal vasoregression in PKD rats 
 
To investigate the effects of intravitreally injected human ASCs on retinal 
vasculature in SD and PKD rats, human ASCs were administrated into the 
vitreous cavity of 1-month-old SD rat eyes. As shown in Fig. 35A, the lenses 
(4/6) of SD rats treated with human ASCs displayed opacity, whereas the lens 
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in the control group remained normal. Compared to that of BMSCs, 
administration of human ASCs adversely affected the retina, as the 
lenses/vitreous usually adhered firmly to the retinas and intravitreal bleeding 
was not noticed frequently. Dot blot analysis demonstrated a significant 
increase in IL-1β expression in the vitreous humor in SD rats (Fig. 35B). 
Compared to that in the controls, remarkable elevation (292%) in acellular 
capillaries and 14% loss in pericytes was observed when rats were treated with 
intravitreal human ASC injection (Fig. 35C-E). Double intravitreal injection of 
human ASCs at postnatal 15 days (P15) and postnatal 30 days (P30) into SD 
rats induced severe lens opacity, strong adherence of the lens to the retina, and 
retinal vascular damage (Fig. 36). Furthermore, we demonstrated that single 
intravitreal injection of human ASCs at P30 led to 50% incidence of lens opacity 
and increased the expression of IL-1β in the vitreous humor of PKD rats. In 
terms of analysis retinal vasculature, intravitreal injection of human ASCs in the 
PKD rats worsened retinal vasoregression, showing an increase in pericyte loss 
by 16%, and formation of acellular capillaries by 103% (Fig. 37). These results 
suggest that intravitreally administrated human ASCs lead to retinal 
vasoregression in SD rats, aggravate retinal vascular damage in PKD rats, and 
upregulate vitreous IL-1β. 
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Figure 35: Intravitreally injected human ASCs lead to cataract formation and 
retinal vasoregression and increase IL-1β expression in vitreous humor in SD 
rats. SD rats were intravitreally injected with PBS (left eye; 2 µL) or ASCs (right eye; 
2 × 104 in 2 µL PBS) at P30. The lens morphology was analyzed 4 weeks post-injection. 
A) ASC injection-induced lens opacity compared to that observed after PBS injection. 
B) Compared to PBS injection, ASC injection increased IL-1β expression in the 
vitreous humor. C-E) Retinal digestion stained with PAS (C) showed that ASC injection 
significantly decreased the number of pericytes (D) and increased acellular capillary 
formation (E) compared to that in the controls. Red arrow indicated acellular capillaries. 
* P < 0.05. 1-hASC: single intravitreal injection of human ASCs. Scale bar = 50 µm. n 
= 6. Permission obtained from copyright © 2019 John Wiley and Sons (Huang et al., 
2019b). 
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Figure 36: Double intravitreal injection of human ASCs induces severe lens 
opacity and retinal vasoregression in SD rats. SD rats were intravitreally injected 
with PBS (left eye; 2 µL) or human ASCs (right eye; 2 × 104 in 2 µL PBS) twice, once 
at P15 and again at P30. Four weeks after injection, lens morphology and pericyte 
coverage, as well as acellular capillary formation, were assessed. A, B) Compared to 
that in the controls, double ASC injection led to severe lens opacity. C-E) Double ASC 
injection significantly increased pericyte loss (D) and acellular capillary formation (E). 
Red arrow indicated acellular capillaries. ** P < 0.01. 2-hASC: double intravitreal 
injection of human ASCs. Scale = 50 µm. n = 5-6. Permission obtained from copyright 
© 2019 John Wiley and Sons (Huang et al., 2019b).  
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Figure 37: Intravitreally injected human ASCs lead to cataract formation and 
retinal vasoregression and increase IL-1β expression in vitreous humor in PKD 
rats. PKD rats were intravitreally injected with PBS (left eye; 2 µL) or ASCs (right eye; 
2 × 104 in 2 µL PBS) at P30. The lens morphology was analyzed 4 weeks post-injection. 
A) ASC injection-induced lens opacity compared to that observed after PBS injection. 
B) Compared to PBS injection, ASC injection increased IL-1β secretion in the vitreous 
humor. Compared to that in the controls, retinal digestion stained with PAS (C) showed 
that ASC injection significantly decreased the number of pericytes (D) and increased 
acellular capillary formation (E). Red arrow indicated acellular capillaries. * P < 0.05; 
*** P < 0.001. 1-hASC: single intravitreal injection of human ASCs. Scale bar = 50 µm. 
n = 6. Permission obtained from copyright © 2019 John Wiley and Sons (Huang et al., 
2019b).  
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3.2.6 Intravitreal injection of HUVECs, RFPECs, and concentrated 
supernatant dose not cause retinal vasoregression in SD rats 
 
To investigate whether retinal vascular damage is caused by MSC injection, we 
further injected either RFPECs or HUVECs (20,000 cells in 2 µL) into vitreous 
space of 1-month-old SD rat eyes. No lens opacity was observed after a 4-week 
injection. More importantly, neither cell type was able to induce pericyte loss 
and formation of acellular capillaries (Fig. 38). These results suggest that retinal 
vasoregression and cataract formation might be closely related to the 
intravitreal administration of MSCs. To evaluate the effect of the conditioned 
medium of MSCs on retinal vasoregression, we intravitreally injected 2 µL 100× 
concentrated human ASC medium into SD rats. We observed that the 
concentrated conditioned medium has neither beneficial nor detrimental effect 
on retinal vasculatures in PKD rats (Fig. 39). Thus, these results suggest that 
HUVECs, RFPECs, and concentrated medium injection cannot enhance retinal 
vascular damage in SD rats. 
 
3.2.7 Intravitreally injected BMSCs do not affect the neuronal function in 
SD and PKD rats 
 
The effect of BMSC injection on retinal neuronal function was evaluated using 
ERG, and retinal histology was evaluated using PAS staining. Compared to that 
observed in control eyes, we did not observe any significant difference in the 
amplitude of a-wave and b-wave in the BMSC-injected eyes in SD and PKD 
rats (Fig. 40). We continued to assess the thickness of the entire retina, 
ganglion cell layer (GCL), inner nuclear layer (INL), and outer nuclear layer 
(ONL) in SD rats treated with BMSCs or PBS. The thickness of the entire retina 
and intra-retinal layers did not show any significant change between the BMSC-
injected and PBS-injected groups in SD rats (Table 17). In addition, statistical 
analysis of cell numbers in the GCL, INL, and ONL showed no significant 
differences in cell numbers in these three layers between BMSC-injected and 
control SD rats (Table 17). Thus, we demonstrate that intravitreally injected rat 
BMSCs do not affect retinal neuronal function and the cell population in retinal 
GCL, INL, and ONL. 
73 
 
 
Figure 38: Intravitreal injection of either RFPECs or HUVECs does not induce 
lens opacity and retinal vasoregression in SD rats. PBS (left eyes; 2 µL) or 
RFPECs/HUVECs (right eyes; 2 × 104 in 2 µL PBS) were injected into the vitreous 
cavity of SD rats at P30. Four weeks after injection, we evaluated the lens opacity and 
retinal vasculature in retinal digest preparations stained with PAS. A, E) Neither 
RFPECs nor HUVECs were able to induce lens opacity. B-D, F-H) Pericyte number (C 
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and G) and acellular capillary number (D and H) in retinal digestion preparations 
stained with PAS (B and F) did not vary significantly between the PBS and 
RFPECs/HUVECs injection groups. RFPECs: rat fat pad endothelial cells; HUVECs: 
human umbilical vein endothelial cells. ns: not significant. Scale = 50 µm. n = 3. 
Permission obtained from copyright © 2019 John Wiley and Sons (Huang et al., 2019b).  
 
 
Figure 39: Intravitreal injection of conditioned media from human ASCs does not 
rescue retinal vasoregression in PKD rats. DMEM (left eyes; 2 µL), or human ASCs 
conditioned media (right eyes; 2 × 104 in 2 µL PBS) was injected into vitreous cavity of 
SD and PKD rats at P30. Four weeks after the injection, retinal vasculature was 
evaluated by staining retinal digest preparations with PAS. A-C) Intravitreally injected 
conditioned media from human ASCs were unable to induce retinal vascular damage 
in SD rats and did not ameliorate pericyte loss and reduce the formation of the acellular 
capillary. SN: supernatant, * P < 0.05; ** P < 0.01; *** P < 0.001. Scale = 50 µm. n = 3. 
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Figure 40: Intravitreally injected BMSCs do not affect neuronal functions in SD 
and PKD rats. SD and PKD rats were intravitreally injected with PBS (left eyes; 2 µL) 
or BMSCs (right eyes; 2 × 104 in 2 µL PBS) at P30. Four weeks after the injection, the 
electrical responses of the retina were measured using ERG. A, B) There were no 
significant differences in a wave (A) and b wave (B) amplitude between PBS and 
BMSC-injected SD rats. C, D) In PKD rats, no significant changes in a wave (C) and b 
wave amplitude (D) were observed between PBS and BMSC injected animals. ns: not 
significant. n = 5-6. Permission obtained from copyright © 2019 John Wiley and Sons 
(Huang et al., 2019b).  
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Table 17: Comparison of the thickness and cell number between PBS and BMSC-injected 
SD retinas. 
    PBS BMSC 
Thickness GCL 10.29 ± 0.59 10.76 ± 2.26 
  INL 28.11 ± 1.92 26.28 ± 3.30 
  ONL 56.08 ± 4.87 49.88 ± 7.71 
  Total retina 355.62 ± 37.45 319.98 ± 48.10 
Cell number GCL 9 ± 1 8 ± 2 
  INL 66 ± 9 62 ± 11 
  ONL 305 ± 46  265 ± 44 
The thicknesses of the entire retina, GCL, INL, and ONL were measured and the number of 
cells in GCL, INL and ONL were counted and expressed in 100 μm retina length for each. There 
were no significant differences in the thickness and cell number in retinal GCL, INL, and ONL 
between SD rats that received PBS and BMSC injections. GCL: ganglion cell layer; INL: inner 
nuclear layer; ONL: outer nuclear layer. n = 6. Permission obtained from copyright © 2019 John 
Wiley and Sons (Huang et al., 2019b). 
 
3.2.8 Intravitreally injected BMSCs activate retinal glial cells in SD rats 
 
Macroglial and microglial cells contribute to the course of pathological retinal 
vasoregression (de Hoz et al., 2016; Seitz et al., 2013). Hence, we investigated 
whether macroglial cells are activated in retinas after intravitreal administration 
of BMSCs. Western blot analysis demonstrated that the level of glial fibrillary 
acidic protein (GFAP), a marker for glial activation, was significantly increased 
in the BMSC-injected retina (Fig. 41A and B). Immunofluorescent data 
demonstrated that GFAP-positive staining was limited in astrocytes of the 
retinal ganglion cell layer (GCL) of PBS-injected SD rat eyes. On the contrary, 
BMSC-injected SD rat eyes displayed robust expression of GFAP in Müller cells, 
suggesting that retinal Müller cells were active when treated with BMSCs (Fig. 
41C). 
 
Next, we evaluated the effect of BMSC injection on the microglial cell population, 
Iba1-positive microglia were quantified in retina. As shown in Fig. 41D and E, 
the number of microglia increased by 130% (34 ± 11 vs. 77 ± 19, SD + PBS vs. 
SD + BMSCs, P < 0.05) in the deep capillary layer where vasoregression had 
been initiated after treatment with BMSCs. Despite the increase in the number 
of microglia, the retinal morphology was similar in both groups. These results 
suggest that intravitreally injected BMSCs can induce microglial recruitment 
without affecting retinal morphology. 
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Figure 41: Intravitreally injected BMSCs activate retinal glial cells in SD rats. A) 
Representative image and quantification of GFAP expression using western blot 
analysis. B) Immunofluorescence staining of GFAP and DRAQ5. Müller cells were 
activated upon BMSC injection. C) Retinal whole-mount preparations stained for Iba1 
(green) and Lectin (red) in SD rats injected with PBS or BMSCs. Upon BMSC injection, 
the number of Iba1-positive microglia increased significantly in the deep capillary layer. 
* P <0.05. BMSC: bone marrow-derived stem cells. GFAP: glial fibrillary acidic protein, 
DRAQ5: nuclear staining, GCL: ganglion cell layer; INL: inner nuclear layer; ONL: outer 
nuclear layer; Iba1: microglial marker. Scale = 50 µm. n=3. Permission obtained from 
copyright © 2019 John Wiley and Sons (Huang et al., 2019b). 
 
3.2.9 BMSC injection-induced retinal vasoregression is associated with 
immune response 
 
To investigate the inflammatory response of the eye to the intravitreally 
administrated BMSCs, we estimated the expression of inflammation-correlated 
factors in the eyes of SD rats. The results of quantitative PCR demonstrated a 
significant increase in IL-1β transcription in the BMSC-treated retinas compared 
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to that in the control retinas. Furthermore, C3 and Arg1, the mediators in retinal 
inflammation and immune response, were significantly upregulated when 
treated with BMSCs (Fig. 42). Neuroprotective factors secreted by the active 
neuroglia can protect neuronal cells against insults. Therefore, we investigated 
the effect of intravitreally injected BMSCs on the expression of retinal 
neuroprotective factors. Interestingly, the expression of NGF, FGF2, CNTF, 
BDGF, and GNDF was comparable between PBS- and BMSC-treated retinas 
(Fig. 43). Taken together, intravitreal BMSC administration-induced retinal 
vasoregression is related to retinal immune and inflammatory response. 
Figure 42: Intravitreally injected BMSCs trigger retinal inflammatory responses 
in SD rats. SD rats were intravitreally injected with PBS (left eye; 2 µL) or BMSCs 
(right eye; 2 × 104 in 2 µL PBS) at P30. Total RNA was extracted from the retinas, and 
inflammation-related factors were analyzed using quantitative PCR 4 weeks post-
injection. BMSC injection significantly increased IL-1β, C3, and Arg1 expression 
compared to that in controls. IL-1β: Interleukin 1 beta; C3: complement component 3; 
Arg1: arginase 1; IL-10: interleukin 10; IL-6: interleukin 6; Cfb: complement factor b. * 
P < 0.05; ** P < 0.01. n = 5. Permission obtained from copyright © 2019 John Wiley 
and Sons (Huang et al., 2019b).  
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Figure 43: Intravitreally injected BMSCs do not promote the expression of retinal 
neurotrophic factors in SD rats. SD rats were intravitreally injected with PBS (left 
eyes; 2 µL) or BMSCs (right eyes; 2 × 104 in 2 µL PBS) at P30. Four weeks after 
injection, total retinal RNA was extracted from SD rats, and retinal neurotrophic factors 
were measured using quantitative PCR. There were no significant differences in the 
expression of NGF, CTNF, BDNF, GDNF, and FGF2 between the PBS and BMSC 
injection groups. NGF: nerve growth factor; CTNF: ciliary neurotrophic factor; BDNF: 
brain-derived neurotrophic factor; GDNF: glial-derived neurotrophic factor; FGF2: 
basic fibroblast growth factor. n = 5. Permission obtained from copyright © 2019 John 
Wiley and Sons (Huang et al., 2019b).  
 
3.2.10 Intravitreally injected BMSCs increase retinal HSP90 expression in 
SD rats 
 
HSPs play an essential role in the protection of cells from damage under 
pathological conditions by enhancing cytoprotective signaling against cell 
damage (Ikwegbue et al., 2018). Therefore, we examined the expression of 
HSP90 using western blot analysis. Compared to that in the controls, significant 
upregulation of retinal HSP90 expression was detected in BMSC-treated eyes 
(Fig. 44A and B). Immunofluorescent images demonstrated visible expression 
of HSP90 in the INL, IPL, and OPL, although weak expression was observed 
in the GCL and INL in PBS-injected SD rats. However, compared to that in the 
controls, intravitreally injected BMSCs induced a stronger expression of HSP90 
in the GCL and, in particular, in the IPL and OPL (Fig. 44C). Furthermore, we 
verified that HSP90 upregulation is derived from macroglial cells, but not from 
vascular cells (Fig. 45). These results indicate that increased expression of 
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HSP90 contributes to cellular protection against BMSC injection. 
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Figure 44: Intravitreally injected BMSCs elevate retinal HSP90 expression in SD 
rats. SD rats were intravitreally injected with PBS (left eye; 2 µL) or BMSCs (right eye; 
2 × 104 in 2 µL PBS) at P30. Four weeks post-injection, retinal HSP90 expression was 
analyzed using western blot analysis and immunofluorescence staining. A) Western 
blot analysis showed that BMSC injection significantly increased HSP90 expression. 
B) Immunofluorescence staining displayed that retinal HSP90 expression (green) in 
BMSC-injected retinas was stronger than that in PBS-injected retinas. HSP90: Heat 
shock protein 90; GCL: ganglion cell layer; INL: inner nuclear layer; ONL: outer nuclear 
layer; DRAQ5: Nuclear staining. * P < 0.05. Scale = 50 µm. n = 3. Permission obtained 
from copyright © 2019 John Wiley and Sons (Huang et al., 2019b).  
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Figure 45: Colocalization of HSP90 with glial cells in the retina. Six-micrometer 
retinal sections were immunolabeled with anti-HSP90 antibody, anti-GFAP antibody (a 
marker for astrocytes and activated Muller cells), lectin antibody conjugated with 
TRITC (retinal vessel marker), and anti-GS antibody (a marker for Muller cells). A) 
Elevated HSP90 did not colocalize with lectin. B) Elevated HSP90 partially colocalized 
with GFAP. C) Elevated HSP90 partially colocalized with GS. The white arrow in B 
indicated the colocalization of HSP90 with GFAP. The insets in C with white lines are 
enlarged images of the area enclosed by dotted lines. GCL: ganglion cell layer; INL: 
inner nuclear layer; ONL: outer nuclear layer; GFAP: glial fibrillary acidic protein; HSP 
90: heat shock protein 90; GS: glutamine synthetase. Scale bar = 50 µm. n = 3. 
Permission obtained from copyright © 2019 John Wiley and Sons (Huang et al., 2019b).  
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4 Discussion  
This study shows the association between endothelial VE-cadherin expression 
and pericyte loss in retinal vasoregression, and for the first time, provides 
evidence that reduced expression of retinal VE-cadherin precedes pericyte loss 
in three retinopathy models. VE-cadherin is essential for endothelial-pericyte 
interaction. Furthermore, we demonstrated that the underlying molecular 
mechanism of VE-cadherin degradation upon NDPK B deficiency or HG in 
endothelial cells involved Src kinase activation, and VE-cadherin tyrosine 
phosphorylation and internalization. In addition, we uncovered the harmful 
effects of intravitreally injected MSCs in rats; we showed that intravitreal 
injection of MSCs induced lens opacity, pericyte loss, glial cell activation, and 
retinal inflammation in rats. 
 
4.1 Adequate expression of VE-cadherin stabilizes pericytes  
 
Retinal pericytes and endothelial cells are the key players in retinal 
microvasculature homeostasis. VE-cadherin is the most studied molecule 
exclusively expressed in endothelial cells, which plays a crucial role in vascular 
integrity. It is known that pericyte loss is the earliest event in early DR (Stewart, 
2016). However, in the present study, we observed reduction in the expression 
of retinal VE-cadherin in a hyperglycemia-dependent model and two 
hyperglycemia-independent models with early retinopathy, which suggested 
that decreased expression of VE-cadherin in retinas precedes pericyte loss and 
is responsible for pericyte loss. Reduction in VE-cadherin expression is a 
common feature of early retinal vasoregression. Furthermore, our in vitro data 
confirmed that VE-cadherin deficiency in endothelial cells leads to pericyte loss. 
 
Indeed, VE-cadherin was essential for vascular development and stability, as 
VE-cadherin null mice died due to severe vascular defects in both 
intraembryonic and extraembryonic vasculatures (Vestweber, 2008). In vitro 
experiments demonstrated that endothelial cells deficient in VE-cadherin did 
not form vascular network and were maintained in a dispersed state (Vittet et 
al., 1997). Capillary tube formation of endothelial cells was inhibited after using 
anti-VE-cadherin blocking antibodies (Bach et al., 1998). The results obtained 
in the present study are in agreement with previous findings, showing that VE-
cadherin is necessary for endothelial-pericyte stability and vascular architecture. 
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Nevertheless, VE-cadherin heterozygous mice appeared phenotypically normal 
and survived to adulthood (Gory-Fauré et al., 1999). Surprisingly, VE-cadherin 
heterozygous mice at postnatal day 5 displayed more pericyte coverage in lung 
capillaries due to increased expression of N-cadherin, which functions to 
increase vascular stability by recruiting pericytes (Giampietro et al., 2012). This 
was in agreement with the notion that VE-cadherin competed with N-cadherin 
expression on the endothelial plasma membrane. When VE-cadherin level was 
decreased, N-cadherin compensated for the reduction in endothelial contact 
(Gerhardt et al., 2000). Whether retinal pericyte coverage is affected in the 
developmental stage and adult stage of VE-cadherin heterozygous mutant 
mice is not clear. The precise mechanism via which VE-cadherin deficiency 
induces pericyte loss is not completely understood. However, we demonstrated 
that adequate VE-cadherin expression in endothelial cells may facilitate 
pericyte stability. 
 
4.2 Endothelial cells with NDPK B deficiency or treated with HG show 
similarities in Src kinase activation, and VE-cadherin phosphorylation, 
internalization, and degradation  
 
VE-cadherin dynamically regulates endothelial barrier function (Gory-Fauré et 
al., 1999). Our study also highlighted that NDPK B-/- mice displayed reduced 
expression of retinal VE-cadherin and increased retinal vascular permeability. 
NDPK B deficiency activated Src kinase, induced VE-cadherin phosphorylation 
(Tyr685), promoted VE-cadherin internalization, and accelerated VE-cadherin 
degradation in endothelial cells, mimicking the impact of high glucose.  
 
Previous studies have provided several lines of evidence indicating that HG 
affects endothelial cell properties and associates with the activation of multiple 
pathways (Davidson and Duchen, 2007; Haidari et al., 2014; Huang and 
Sheibani, 2008; Qiu et al., 2016). Src kinase regulates vascular permeability. 
Reports show that Src kinase activity increases in mice with diabetes, and that 
HG activates the Src signaling pathway to enhance endothelial cell migration 
(Schaeffer et al., 2003; Xie et al., 2013). Herein, our results were consistent 
with early findings showing that HG promotes Src tyrosine phosphorylation in 
endothelial cells. Importantly, NDPK B deficiency and HG produced similar 
effects on the increase in Src phosphorylation. This outcome is contrary to the 
observations of a previous study, which has suggested that NDPK B depletion 
in endothelial cells abolishes VEGF-induced Src phosphorylation (Gross et al., 
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2017). Based on these results, we inferred that NDPK B may play a diverse 
role in the regulation of Src activity under different stimuli. However, in the 
present study, we did not investigate how NDPK B deficiency or HG treatment 
of endothelial cells increases Src activity. A possible explanation for this might 
be the disruption of phosphate and energy homeostasis caused by NDPK B 
depletion or HG treatment in endothelial cells, which might induce Src kinase 
tyrosine phosphorylation or alter the biological properties of Src kinase 
substrates.   
 
The Src signaling pathway mediates VE-cadherin function. Src kinase activity 
is essential for VEGF-induced VE-cadherin phosphorylation (Tyr 685), which 
results in the opening of the gap between endothelial cells and increase in 
vascular permeability (Sidibé et al., 2014). HG also induced VE-cadherin 
phosphorylation (Tyr658 and Tyr731), which increased endothelial permeability 
(Rangasamy et al., 2011). Another study reported that endothelial cells 
stimulated with HG lead to VE-cadherin phosphorylation via PKC-β-dependent 
myosin light chain (MLC) phosphorylation. In the present study, we showed that 
NDPK B deficiency or HG exclusively increased VE-cadherin phosphorylation 
(Tyr 685) by upregulating Src kinase activity in endothelial cells.   
 
VE-cadherin phosphorylation mediates internalization. Therefore, excessive 
internalized VE-cadherin leads to reduction in membranous VE-cadherin 
expression. Reports show that NDPK B contributes to adhesion junction 
integrity and plays a central role in the regulation of endocytosis (Feng et al., 
2014; Snider et al., 2015). The loss of NDPK B interfered with the barrier 
function in the brain (Gross et al., 2017). HG enhanced horseradish peroxidase 
endocytosis in retinal vascular endothelial cells (Stitt et al., 1995). Our present 
study showed that NDPK B deficiency or HG treatment in endothelial cells 
promoted VE-cadherin internalization, which conversely reduced the 
expression of plasma membrane VE-cadherin. We further observed that 
internalized VE-cadherin is first captured by early endosome, and afterward is 
trapped into the lysosome for degradation. These results showed for the first 
time that NDPK B participates in the regulation of VE-cadherin endocytosis and 
plays a protective role in VE-cadherin degradation. The loss of NDPK B in 
endothelial cells mimics HG-mediated lysosomal VE-cadherin degradation.  
 
Recent reports have demonstrated that Ras-related proteins 11 (Rab11) plays 
an essential role in VE-cadherin recycling. Reduced expression of Rab11 
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inhibited VE-cadherin recycling to the membrane, leading to increased vascular 
leakage in mice when treated with stimuli (Yan et al., 2015). Whether NDPK B 
loss or HG treatment in endothelial cells is involved in the Rab11-mediated VE-
cadherin recycling pathway is still unknown. Furthermore, microRNAs also 
regulate VE-cadherin degradation. For example, miR-939 and miR-27a-3p 
target VE-cadherin and mediate the downregulation of VE-cadherin (Di Modica 
et al., 2017; Zhao et al., 2016). In the present study, we did not analyze the 
expression of microRNA, but instead analyzed the mRNA expression of VE-
cadherin in NDPK B-depleted or HG-treated endothelial cells, showing that the 
mRNA level of junctional molecules, including VE-cadherin, is unaffected in 
either NDPK B deficient or HG-treated endothelial cells. These data further 
demonstrated that NDPK B mediates VE-cadherin expression in the post-
translation modification process rather than in the transcriptional process. In 
addition, reduced expression of p120-catenin promotes VE-cadherin 
endocytosis. However, the results of this study do not support those of previous 
studies. We observed that the expression of p120-catenin is unaltered in NDPK 
B-depleted or HG-treated endothelial cells, which suggests that the reduced 
expression of VE-cadherin in endothelial cells caused by NDPK B deficiency or 
HG is independent of p120 catenin.  
 
Studies have suggested that vascular endothelial protein tyrosine phosphatase 
(VE-PTP) interacts with VE-cadherin, reducing VE-cadherin tyrosine 
phosphorylation to maintain cell layer permeability (Nottebaum et al., 2008). 
Dissociation of VE-PTP and VE-cadherin weakens cellular junctions and 
promotes leukocyte extravasation (Broermann et al., 2011). This observation 
supports the hypothesis that NDPK B may facilitate the stabilization of VE-PTP 
and VE-cadherin, preventing VE-cadherin trafficking into the cytosol. 
 
4.3 Evaluation of intravitreally injected MSCs in pre-clinical and clinical 
studies 
 
Another key finding of the study was the unexpected induction of 
vasoregression upon intravitreal administration of MSCs in both healthy and 
diseased retinas. In addition to the vascular damage, intravitreal injection of 
MSCs led to cataract, activation of retinal glial cells, and elevation of 
inflammatory factors. This is opposite to early published results, the majority of 
which have reported that MSCs have beneficial vasoprotective and pro-
angiogenic effects in experimental animal models of DR and other retinal 
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diseases (Elshaer et al., 2018; Otani et al., 2004). Mendel et al. (2013) 
demonstrated that intravitreal injection of MSCs prevented retinal capillary loss 
in mouse models of DR and hypoxia-induced proliferative retinopathy. The 
regenerative capacity of intravitreally administrated human ASCs in the diabetic 
rat retinas was also verified by Rajashekhar and colleagues (Rajashekhar et al., 
2014). In addition, intravitreally injected MSCs can migrate into the retinal outer 
nuclear layer, differentiate into neural cells in injured rat retinas (Tomita et al., 
2002), or into retinal microglia, Müller cells, and endothelial cells (Chakravarthy 
et al., 2016). In contrast, we observed a vasoregressive instead of a 
vasoprotective effect after the intravitreal injection of MSCs in healthy and 
diseased retinas. The vasoregressive damage typically seen in the diseased 
retinas was further exacerbated by MSC injection (Huang et al., 2019a). 
 
Despite numerous encouraging and promising in vivo and in vitro results 
supporting MSC therapy, adverse cases have been reported by early studies, 
such as detrimental outcomes in stem cell therapy against eye diseases. 
Kuriyan et al. described complete vision loss in a patient with age-related 
macular degeneration after intravitreal injection with autologous stem cells 
(Kuriyan et al., 2017). Likewise, Satarian et al. have reported that intravitreal 
injection of autologous BMSCs into patients with advanced retinitis pigmentosa 
induced further retinal vascular deterioration, causing severe vision impairment 
(Satarian et al., 2017). These adverse outcomes indicated that MSC-based 
therapy might have bidirectional effects, protective as well as destructive, on 
the retinal vasculature. Determining the efficiency and safety of intravitreal stem 
cell injections for clinical application in DR and retinal degenerative diseases is 
of crucial importance. 
 
Whether intravitreally injected MSCs can migrate into the retina and integrate 
with retinal vessels is still being debated (Ezquer et al., 2016). Intriguingly, our 
results have shown that intravitreally injected MSCs did not migrate into the 
retinas, supporting the observation by Johnson et al. who demonstrated that 
the existence of a completely developed inner limiting membrane hinders the 
passage of injected MSCs into the retinas (Johnson et al., 2010b). These data 
suggest that MSC-based therapy may be effective only in the immature retina. 
Some models in which therapeutic efficacy has been tested include retinopathy 
of prematurity (ROP) models in which vasoregression is caused by hyperoxia 
in immature retinal vessels (Connor et al., 2009). The retinal vascular structure 
is not entirely developed in those models, allowing the intravitreally injected 
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cells to migrate into the retina. Whether MSCs can produce beneficial effects 
may be dependent on the model, as immunomodulation may exert distinct 
effects in these models, such as the PKD model with excessive inflammatory 
components. 
 
4.4 Intravitreally injected MSCs induce inflammatory responses 
 
Interspecies MSCs have been applied in experimental studies for stem cell 
therapy, such as the usage of human MSCs in rodent models with retinal 
diseases. Preservation of retinal functions was determined after treatment of 
animal models with human MSCs (Wang et al., 2017; Yang et al., 2010; Zhang 
et al., 2017). We observed that MSCs from human sources induced more 
severe retinal vasoregression than allogeneic MSCs in rats. Furthermore, we 
demonstrated compellingly that MSCs themselves trigger vasoregression in the 
retina via increased inflammatory responses, in contrast to autologous or 
xenogeneic endothelial cells, which are inert. In contrast to mature endothelial 
cells, MSCs are multipotent cells that can differentiate into various cell types. 
As the injected MSCs did not penetrate the retinas, the induced vasoregression 
may not be due to the direct effect of migrated and differentiated BMSCs in the 
retinas. Based on the high microglia number and pro-inflammatory cytokines in 
the vitreous and/or retinas, we postulated that MSCs may provoke an immune-
inflammatory response, indirectly causing retinal vascular damage. The key 
role of inflammation in the development of vascular damage in DR and retinal 
degeneration is evident (Rangasamy et al., 2012). Increased levels of pro-
inflammatory cytokines such as IL-1β, IL-6, and TNF have been reported in 
these diseases. In our study, we also detected increase in IL-1β level in the 
vitreous and, to a lesser extent, in the retinas of stem cell-injected SD rats. 
Concurrently, C3 and Arg1 were upregulated in the retinas upon MSC injection. 
The results suggest a potential connection between immune-inflammatory 
responses and MSC treatment, supporting reports showing that pro-
inflammatory cytokines mediated vascular damage. In addition, our data 
demonstrated that intravitreally injected MSCs induce lens opacity in both SD 
and PKD eyes. No cataract formation was observed in the control PKD eyes, 
although IL-1β expression in the retinas was increased (Feng et al., 2011). 
Therefore, the increased IL-1β level in the vitreous after BMSC injection is 
unlikely to be a cause of cataract, which remains to be further elucidated. Pro-
inflammatory cytokines in the retina are mainly produced by activated microglial, 
macroglial, and endothelial cells (Altmann and Schmidt, 2018). Our results 
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revealed high numbers of microglial cells in the BMSC-treated retinas, 
suggesting that microglial cells mainly contribute to the inflammatory response 
when treated with stem cells in retinas. Furthermore, activation of Müller cells 
in the retina was observed upon MSC intravitreal injection. However, whether 
the inflammatory response is a critical mediator in the development of retinal 
vasoregression after MSC application requires further investigation.  
 
Activated Müller cells exhibit dual functions of promoting vasoregression and 
protecting the retinal neuronal cells (Abcouwer, 2017; Fu et al., 2015). While 
vasoregression was observed in our study, no changes in neurotrophic factors 
or neuronal function were observed post-injection of MSCs. Our study was 
designed for a short-term period after MSC therapy. MSCs may have a 
neuroprotective effect in long-term application. MSC treatment possibly 
activated cytoprotective signaling pathways in our study, as the expression of 
HSP90 was significantly upregulated in the retina and partially in the Müller 
cells. HSP90 is universally expressed in the retina and plays diverse roles in 
retinal disorders (Kojima et al., 1996; Urbak and Vorum, 2010). HSP90 
inhibitors are used in the treatment of patients with retinitis pigmentosa, AMD, 
and ocular oncology, indicating that the inhibition of HSP90 protects the retinal 
cells against cellular damage by affecting the inflammatory and angiogenic 
responses (Aguilà and Cheetham, 2016; Aguila et al., 2013). Elevated level of 
HSP90 after MSC treatment is possibly associated with the inflammation-
induced cytoprotective loop in the retina to promote cell survival.      
 
Although the eye is considered as an immune-privileged organ, low-grade 
inflammation may exist, especially after intravitreal injections. In one clinical 
study, Siqueira et al. showed that the improvement of vision-correlated life 
quality scores in patients at 3 months after treatment disappeared at 12 months 
(Siqueira et al., 2015). Most of the published animal studies were planned as 
short-term studies with treatment duration of months. In this study, significant 
aggravation of retinal vasoregression without neuronal function alteration was 
observed in MSC-treated eyes. We postulated that the result of persistent 
vasoregression will impair the retinal neuronal function in SD and PKD rats. 
Whether the vanishment of protective effect of MSC-based therapy at 12 
months post-treatment in the clinical trials reported by Siqueira et al. is caused 
by MSC-induced indirect vascular damage followed by alteration of neuronal 
cell function is not clear.   
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4.5 Further studies 
In this study, we have reported that reduced VE-cadherin expression in retinas 
precedes pericyte loss in retinopathy models. The loss of VE-cadherin in 
endothelial cells leads to pericyte detachment. Further research should be 
undertaken to investigate whether VE-cadherin heterozygote mice exhibit 
pericyte loss in retinas. NDPK B loss or HG treatment in endothelial cells can 
promote VE-cadherin internalization via increased Tyr 685 phosphorylation 
mediated by Src kinase activation, suggesting that Tyr 685 residue is required 
for VE-cadherin internalization. Despite these promising results, questions 
remain whether NDPK B loss or HG treatment in the endothelial cells induce 
VE-cadherin internalization after mutation of VE-cadherin Tyr 685. 
 
The endocytosis pathway can be mainly classified into the clathrin-mediated 
pathway and the caveolae-mediated pathway. Although we already know that 
NDPK B loss or HG treatment of endothelial cells promotes membrane VE-
cadherin internalization and lysosome-mediated degradation, the identity of the 
cellular endocytosis pathway involved remains unclear. NDPK B loss and HG 
treatment of endothelial cells might mediate VE-cadherin endocytosis via the 
different pathways. Furthermore, early studies had revealed that NDPK B 
interacts with dynamin, which is an essential regulator of endocytosis. NDPK B 
binding to dynamin may facilitate the homeostasis of membrane protein 
trafficking. NDPK B deficiency possibly leads to the dissociation of NDPK B and 
dynamin, which increases endocytosis. Studies have shown that NDPK B 
interacts with α-catenin, which is indirectly bound to the VE-cadherin complex 
on the membrane. Thus, the possible regulation of VE-cadherin upon NDPK B 
deficiency via α-catenin is not excluded. 
 
Furthermore, how NDPK B loss or HG treatment of endothelial cells promotes 
internalized VE-cadherin transportation to the lysosome is still obscure. The 
recycling pathway may be involved, as some crucial regulators such as Rab11 
and Rab7 play a vital role in the regulation of VE-cadherin recycling. NDPK B 
loss or HG in endothelial cells might affect the function of these molecules, 
which might delay the return of the internalized VE-cadherin to the plasma 
membrane or drive internalized VE-cadherin to the lysosome.  
 
Contrary to expectations, this study does not show the protective roles of 
intravitreally injected MSCs in PKD rats; instead, it shows that intravitreally 
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injected MSCs induce cataract, pericyte loss, glial cell reactivation, and 
inflammation in rat eyes. Compared to traditional drug therapy for eye diseases, 
MSC-based therapy is associated with several potential risks, such as 
uncontrolled cellular property and unclear mechanism of action. MSCs are 
heterogeneous in nature and behave differently in the same environment. Thus, 
cell quality should be controlled and the differentiation potential and biological 
activity of MSCs should be elucidated prior to injection. To circumvent this 
problem, we propose the evaluation of cells in animal research before use in 
patients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
92 
 
5 Summary  
 
Pericytes and endothelial cells are the major players in maintaining retinal 
neurovascular unit (NVU) integrity. Pericytes contribute to vascular protection 
and regeneration in the retina. Previous studies have reported pericyte loss in 
several animal models of retinopathy with the breakdown of NVU, such as in 
NDPK B-/- mice (5-month-old), PKD rats (2-month-old), and Ins2Akita mice (3-
month old). VE-cadherin is exclusively expressed in endothelial cells and 
preserves the endothelial barrier functions. Reduced expression of VE-
cadherin leads to increased vascular permeability. However, the correlation 
between altered VE-cadherin expression and pericyte loss and the underlying 
mechanism are still not clear. From the therapeutic perspective, pericytes have 
been therapeutic targets for diseases with retinal vascular degeneration. 
Mesenchymal stem cells (MSCs) and pericytes share typical cell morphology 
and phenotypic characteristics. Thus, MSC-based therapy has been proposed 
as an alternative therapeutic approach in retinal degenerative diseases. 
Therefore, the study aims were to identify: 1) the link between retinal VE-
cadherin expression and pericyte loss in animal models with vasoregressive 
retinopathy, and the underlying signal transduction; 2) the therapeutic potential 
of intravitreally administrated MSCs in retinopathy with vasoregression.  
The following are the key observations of this study:  
1. Reduced VE-cadherin expression was observed in the retinas of 4-month-
old NDPK B-/- mice, 1.5-month-old Ins2Akita mice, and 1-month-old PKD rats 
prior to pericyte loss.  
2. Retinal vascular permeability was increased in NDPK B-/- mice. Reduced VE-
cadherin expression was predominantly detected in the deep retinal capillary 
layer.  
3. In vitro, either NDPK B deficiency or HG lowered VE-cadherin in the 
endothelial plasma membrane by promoting Src kinase activation, followed 
by VE-cadherin tyrosine phosphorylation (Y685), leading to internalization 
and degradation in a lysosome-dependent manner. Furthermore, reduced 
expression of VE-cadherin led to pericyte loss in endothelial cells.   
4. Intravitreal administration of MSCs in both SD and PKD eyes induced or 
aggravated cataract, pericyte loss, and formation of acellular capillaries.  
5. MSCs remained in the vitreous cavity and did not migrate into the retinas.  
6. Intravitreal administration of MSCs impacted retinal neuronal function neither 
in SD nor PKD rats. 
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7. Intravitreal injection of MSCs activated retinal micro- and microglial cells in 
SD rats. 
8. Intravitreal injection of MSCs increased the expression of inflammatory 
factors (IL-1β, C3, and Arg1) and enhanced HSP90 expression in SD rats.  
 
In conclusion, our results suggest that the alteration of retinal VE-cadherin 
expression precedes pericyte loss independent of hyperglycemia in different 
experimental animal models with early retinopathy. VE-cadherin reduction 
induces pericyte loss via Src kinase activation and increased VE-cadherin Y685 
phosphorylation. We identify a novel signaling pathway involved in VE-
cadherin-mediated pericyte loss, which provides new insights regarding 
therapeutic intervention in retinopathy with NVU breakdown. However, the 
destructive effect of MSCs in eyes indicates that intravitreal administration of 
MSCs is inadvisable. 
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